<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id>
<journal-title-group>
<journal-title>Pharmaceuticals</journal-title>
</journal-title-group>
<issn pub-type="epub">1424-8247</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32414180</article-id>
<article-id pub-id-type="pmc">7281272</article-id>
<article-id pub-id-type="doi">10.3390/ph13050095</article-id>
<article-id pub-id-type="publisher-id">pharmaceuticals-13-00095</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Molecular Mechanisms of the Teratogenic Effects of Thalidomide</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Asatsuma-Okumura</surname>
<given-names>Tomoko</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9997-2664</contrib-id>
<name>
<surname>Ito</surname>
<given-names>Takumi</given-names>
</name>
<xref ref-type="corresp" rid="c1-pharmaceuticals-13-00095">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6656-9521</contrib-id>
<name>
<surname>Handa</surname>
<given-names>Hiroshi</given-names>
</name>
</contrib>
</contrib-group>
<aff id="af1-pharmaceuticals-13-00095">Department of Chemical Biology, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan; <email>tokumura@tokyo-med.ac.jp</email> (T.A.-O.); <email>hhanda@tokyo-med.ac.jp</email> (H.H.)</aff>
<author-notes>
<corresp id="c1-pharmaceuticals-13-00095"><label>*</label>Correspondence: <email>takumii@tokyo-med.ac.jp</email>; Tel.: +81-3-9323-3250; Fax: +81-3-9323-3251</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2020</year>
</pub-date>
<volume>13</volume>
<issue>5</issue>
<elocation-id>95</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Thalidomide was sold worldwide as a sedative over 60 years ago, but it was quickly withdrawn from the market due to its teratogenic effects. Thalidomide was later found to have therapeutic effects in several diseases, although the molecular mechanisms remained unclear. The discovery of cereblon (CRBN), the direct target of thalidomide, a decade ago greatly improved our understanding of its mechanism of action. Accumulating evidence has shown that CRBN functions as a substrate of Cullin RING E3 ligase (CRL4<sup>CRBN</sup>), whose specificity is controlled by ligands such as thalidomide. For example, lenalidomide and pomalidomide, well-known thalidomide derivatives, degrade the neosubstrates Ikaros and Aiolos, resulting in anti-proliferative effects in multiple myeloma. Recently, novel CRBN-binding drugs have been developed. However, for the safe handling of thalidomide and its derivatives, a greater understanding of the mechanisms of its adverse effects is required. The teratogenic effects of thalidomide occur in multiple tissues in the developing fetus and vary in phenotype, making it difficult to clarify this issue. Recently, several CRBN neosubstrates (e.g., SALL4 (Spalt Like Transcription Factor 4) and p63 (Tumor Protein P63)) have been identified as candidate mediators of thalidomide teratogenicity. In this review, we describe the current understanding of molecular mechanisms of thalidomide, particularly in the context of its teratogenicity.</p>
</abstract>
<kwd-group>
<kwd>thalidomide</kwd>
<kwd>cereblon</kwd>
<kwd>ubiquitin</kwd>
<kwd>lenalidomide</kwd>
<kwd>protein degradation</kwd>
<kwd>PROTACs</kwd>
<kwd>teratogenicity</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-pharmaceuticals-13-00095" sec-type="intro">
<title>1. Introduction</title>
<p>Thalidomide (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f001">Figure 1</xref>A) was first developed by Chemie Grünenthal (West Germany) in 1957 and was soon in use worldwide as a sedative. The use of thalidomide spread to more than 40 countries, but this drug was withdrawn from the market in 1961, as it was revealed to cause teratogenicity when taken during early pregnancy [<xref ref-type="bibr" rid="B1-pharmaceuticals-13-00095">1</xref>,<xref ref-type="bibr" rid="B2-pharmaceuticals-13-00095">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceuticals-13-00095">3</xref>,<xref ref-type="bibr" rid="B4-pharmaceuticals-13-00095">4</xref>]. Clinical studies, however, demonstrated the therapeutic efficacy of thalidomide in several intractable diseases. First, in 1965, thalidomide was reported to be effective in erythema nodosum leprosum (ENL), an inflammatory complication of leprosy [<xref ref-type="bibr" rid="B5-pharmaceuticals-13-00095">5</xref>]. During the 1980s to early 1990s, thalidomide was shown to be effective in certain autoimmune diseases such as rheumatoid arthritis, Behcet’s disease, and chronic graft versus host disease [<xref ref-type="bibr" rid="B6-pharmaceuticals-13-00095">6</xref>,<xref ref-type="bibr" rid="B7-pharmaceuticals-13-00095">7</xref>,<xref ref-type="bibr" rid="B8-pharmaceuticals-13-00095">8</xref>,<xref ref-type="bibr" rid="B9-pharmaceuticals-13-00095">9</xref>]. Furthermore, in the early 1990s, thalidomide was reported to inhibit tumor necrosis factor (TNF)-alpha production and human immunodeficiency virus (HIV) replication [<xref ref-type="bibr" rid="B10-pharmaceuticals-13-00095">10</xref>,<xref ref-type="bibr" rid="B11-pharmaceuticals-13-00095">11</xref>,<xref ref-type="bibr" rid="B12-pharmaceuticals-13-00095">12</xref>]. In 1994, thalidomide was demonstrated to have anti-angiogenic activity, which suggested anti-cancer activity [<xref ref-type="bibr" rid="B13-pharmaceuticals-13-00095">13</xref>]. In 1999, thalidomide was shown to be effective against multiple myeloma, a malignant B cell lymphoma [<xref ref-type="bibr" rid="B14-pharmaceuticals-13-00095">14</xref>]. Based on these findings, in 1998 and 2006, thalidomide was approved by the Food and Drug Administration (FDA) for the treatment of ENL and multiple myeloma, respectively [<xref ref-type="bibr" rid="B15-pharmaceuticals-13-00095">15</xref>,<xref ref-type="bibr" rid="B16-pharmaceuticals-13-00095">16</xref>]. As the precise molecular mechanisms of thalidomide teratogenicity remains unclear, thalidomide prescription is strictly controlled by a program called the Thalidomide Risk Evaluation and Mitigation Strategy (REMS), formerly known as the System for Thalidomide Education and Prescribing Safety (STEPS) [<xref ref-type="bibr" rid="B17-pharmaceuticals-13-00095">17</xref>,<xref ref-type="bibr" rid="B18-pharmaceuticals-13-00095">18</xref>]. In Brazil, however, where leprosy is a common disease among the poor, the use of thalidomide led to a tragic increase in birth defects. Although the package was marked with a pictogram to prohibit its use by pregnant women, it was mistaken for a contraceptive due to poor literacy. Elucidating the molecular mechanisms of thalidomide embryopathy remains an urgent matter [<xref ref-type="bibr" rid="B19-pharmaceuticals-13-00095">19</xref>,<xref ref-type="bibr" rid="B20-pharmaceuticals-13-00095">20</xref>,<xref ref-type="bibr" rid="B21-pharmaceuticals-13-00095">21</xref>].</p>
<p>As the therapeutic efficacy of thalidomide was demonstrated, many thalidomide derivatives with greater potency were developed, yet the molecular mechanisms underlying the effects of thalidomide, such as inhibition of oxidative stress or angiogenesis, remained uncertain [<xref ref-type="bibr" rid="B22-pharmaceuticals-13-00095">22</xref>,<xref ref-type="bibr" rid="B23-pharmaceuticals-13-00095">23</xref>,<xref ref-type="bibr" rid="B24-pharmaceuticals-13-00095">24</xref>,<xref ref-type="bibr" rid="B25-pharmaceuticals-13-00095">25</xref>]. The most important question was to identify the direct target of thalidomide.</p>
<p>A decade ago, we identified cereblon (CRBN) as a primary target of thalidomide teratogenicity [<xref ref-type="bibr" rid="B26-pharmaceuticals-13-00095">26</xref>]. Since then, our understanding of the mechanisms of action of thalidomide have advanced significantly. Currently, CRBN is thought to act basically as a subunit of a ligand-dependent E3 ubiquitin ligase complex whose substrate recognition can be controlled by thalidomide or its related compounds [<xref ref-type="bibr" rid="B27-pharmaceuticals-13-00095">27</xref>]. CRBN is required for both the teratogenic effects and the therapeutic effects of thalidomide and its derivatives. Recently, CRBN-binding drugs have vividly been developed [<xref ref-type="bibr" rid="B28-pharmaceuticals-13-00095">28</xref>]. In this review, we introduce the basic functions of CRBN and discuss our current understanding of the molecular mechanisms of thalidomide, mainly focusing on its teratogenicity.</p>
</sec>
<sec id="sec2-pharmaceuticals-13-00095">
<title>2. Teratogenic Activity of Thalidomide</title>
<p>When pregnant women took thalidomide between day 20 and day 36 after fertilization, multiple birth defects occurred [<xref ref-type="bibr" rid="B29-pharmaceuticals-13-00095">29</xref>]. A single tablet (50 mg) of thalidomide was enough to induce developmental defects [<xref ref-type="bibr" rid="B29-pharmaceuticals-13-00095">29</xref>]. A broad spectrum of birth defects was reported, including malformations of the limb, ear, eye, internal organs, face, genitalia, and central nervous system [<xref ref-type="bibr" rid="B29-pharmaceuticals-13-00095">29</xref>,<xref ref-type="bibr" rid="B30-pharmaceuticals-13-00095">30</xref>,<xref ref-type="bibr" rid="B31-pharmaceuticals-13-00095">31</xref>]. Even during the thalidomide-sensitive time period, by comparison, the earlier stages are particularly prone to more serious damages. First, the damage caused by taking thalidomide between day 20 and day 24 after fertilization appears as missing external ear. Thalidomide intake after day 24 causes multiple phenotypes such as damage in the inner ear, ear deformation, ocular anomalies, and upper limb damage (phocomelia, amelia), or hip dislocation. Damage to the lower limbs is seen in the comparatively late intake of the drug during the thalidomide sensitive time window, which is after day 27. Malformations in thumbs are seen by taking thalidomide from day 24 and even after day 31 [<xref ref-type="bibr" rid="B29-pharmaceuticals-13-00095">29</xref>]. The mortality rate for infants with thalidomide-induced birth defects was reported to be 30%–40%. Thalidomide caused imperforate anus and other gastrointestinal deformities in many infants, contributing to early death [<xref ref-type="bibr" rid="B31-pharmaceuticals-13-00095">31</xref>,<xref ref-type="bibr" rid="B32-pharmaceuticals-13-00095">32</xref>]. In addition, an unknown number of miscarriages were caused by thalidomide.</p>
<p>Limb defects were very frequently observed [<xref ref-type="bibr" rid="B31-pharmaceuticals-13-00095">31</xref>]. Both upper limbs and lower limbs were affected by thalidomide. Two types of limb defects are induced by thalidomide, phocomelia and amelia. The limb is composed of the stylopod, zeugopod, and autopod. Phocomelia describes an abnormal limb with a stylopod, a truncated or absent zeugopod, and a nearly intact autopod, while amelia is a complete loss of the limb [<xref ref-type="bibr" rid="B29-pharmaceuticals-13-00095">29</xref>,<xref ref-type="bibr" rid="B33-pharmaceuticals-13-00095">33</xref>,<xref ref-type="bibr" rid="B34-pharmaceuticals-13-00095">34</xref>]. Polydactyly was also observed in deformed limbs, including phocomelia [<xref ref-type="bibr" rid="B1-pharmaceuticals-13-00095">1</xref>,<xref ref-type="bibr" rid="B29-pharmaceuticals-13-00095">29</xref>,<xref ref-type="bibr" rid="B35-pharmaceuticals-13-00095">35</xref>,<xref ref-type="bibr" rid="B36-pharmaceuticals-13-00095">36</xref>]. Defects of the shoulder and hip joint points were reported [<xref ref-type="bibr" rid="B34-pharmaceuticals-13-00095">34</xref>]. Auricular defects were also very frequently observed, including anotia, mild malformation of the external ear, and hearing loss [<xref ref-type="bibr" rid="B29-pharmaceuticals-13-00095">29</xref>,<xref ref-type="bibr" rid="B31-pharmaceuticals-13-00095">31</xref>,<xref ref-type="bibr" rid="B35-pharmaceuticals-13-00095">35</xref>]. Ocular anomalies included uveal coloboma, glaucoma, and microphthalmia. With respect to the internal organs, kidney malformations, heart defects, and structural chest defects were frequently observed [<xref ref-type="bibr" rid="B34-pharmaceuticals-13-00095">34</xref>,<xref ref-type="bibr" rid="B37-pharmaceuticals-13-00095">37</xref>,<xref ref-type="bibr" rid="B38-pharmaceuticals-13-00095">38</xref>]. Facial palsy and facial asymmetry were also common [<xref ref-type="bibr" rid="B31-pharmaceuticals-13-00095">31</xref>,<xref ref-type="bibr" rid="B35-pharmaceuticals-13-00095">35</xref>]. Thalidomide was also reported to potentially affect facial muscles and facial nerves [<xref ref-type="bibr" rid="B29-pharmaceuticals-13-00095">29</xref>,<xref ref-type="bibr" rid="B31-pharmaceuticals-13-00095">31</xref>,<xref ref-type="bibr" rid="B35-pharmaceuticals-13-00095">35</xref>]. Autism and intellectual disability were also reported [<xref ref-type="bibr" rid="B31-pharmaceuticals-13-00095">31</xref>,<xref ref-type="bibr" rid="B35-pharmaceuticals-13-00095">35</xref>,<xref ref-type="bibr" rid="B39-pharmaceuticals-13-00095">39</xref>].</p>
<p>Thalidomide causes limb defects in humans, monkeys, rabbits, chicks, and zebrafish [<xref ref-type="bibr" rid="B27-pharmaceuticals-13-00095">27</xref>,<xref ref-type="bibr" rid="B30-pharmaceuticals-13-00095">30</xref>,<xref ref-type="bibr" rid="B33-pharmaceuticals-13-00095">33</xref>]. In monkeys and rabbits, both amelia and phocomelia occur. In chicks, only amelia occurs [<xref ref-type="bibr" rid="B33-pharmaceuticals-13-00095">33</xref>]. In zebrafish, thalidomide inhibits the development of the pectoral fins along the proximodistal axis [<xref ref-type="bibr" rid="B26-pharmaceuticals-13-00095">26</xref>,<xref ref-type="bibr" rid="B40-pharmaceuticals-13-00095">40</xref>,<xref ref-type="bibr" rid="B41-pharmaceuticals-13-00095">41</xref>]. Although the fin is structurally different from the limb in mammals and chicks, the molecular pathways are evolutionary conserved. Thalidomide inhibits chondrogenic differentiation in pectoral fins. Pectoral fins are composed of the endoskeletal disc, the scapulocoracoid, and the cleithrum. Thalidomide treatment in the early stage of development resulted in severe defects in chondrogenesis and retardation of the endoskeletal disc and cleithrum [<xref ref-type="bibr" rid="B40-pharmaceuticals-13-00095">40</xref>]. Rodents are resistant to limb deformities induced by thalidomide. It was reported that thalidomide did not induce limb defects in rats even at doses of up to 4000 mg/kg [<xref ref-type="bibr" rid="B42-pharmaceuticals-13-00095">42</xref>]. Why mice and rats are resistant to thalidomide teratogenicity remains unknown.</p>
<p>In vertebrates, fibroblast growth factor 8 (FGF8) is essential for the development of limbs, including fins [<xref ref-type="bibr" rid="B43-pharmaceuticals-13-00095">43</xref>,<xref ref-type="bibr" rid="B44-pharmaceuticals-13-00095">44</xref>]. FGF8 is expressed in the apical ectodermal ridge (AER), the distalmost end of the developing limbs. Thalidomide was shown to reduce the expression of FGF8 in the AER in rabbits, chicks and zebrafish [<xref ref-type="bibr" rid="B26-pharmaceuticals-13-00095">26</xref>,<xref ref-type="bibr" rid="B45-pharmaceuticals-13-00095">45</xref>]. Downregulation of FGF8 leads to induction of pro-apoptotic genes and therefore to malformation of the limbs. Therefore, the effects of thalidomide are likely mediated through evolutionarily common signal transduction pathways in different vertebrates.</p>
</sec>
<sec id="sec3-pharmaceuticals-13-00095">
<title>3. The Direct Target of Thalidomide</title>
<p>In 2010, the identification of CRBN as a thalidomide-binding protein represented a major advance in understanding the molecular mechanism of thalidomide [<xref ref-type="bibr" rid="B26-pharmaceuticals-13-00095">26</xref>]. We immobilized various small chemical bioactive compounds onto ferrite glycidyl methacrylate (FG) beads to study their targets [<xref ref-type="bibr" rid="B46-pharmaceuticals-13-00095">46</xref>,<xref ref-type="bibr" rid="B47-pharmaceuticals-13-00095">47</xref>,<xref ref-type="bibr" rid="B48-pharmaceuticals-13-00095">48</xref>]. Affinity purification using thalidomide-immobilized FG beads led to the identification of CRBN and DNA damage-binding protein 1 (DDB1) as thalidomide-binding proteins. The function of CRBN was unknown at the time, although it was thought to be related to mental retardation and intellectual disability [<xref ref-type="bibr" rid="B49-pharmaceuticals-13-00095">49</xref>]. A clue to the function of CRBN was DDB1, the protein co-purified with CRBN. DDB1 forms a complex with Cullin RING type E3 ubiquitin ligase (CRL4) [<xref ref-type="bibr" rid="B50-pharmaceuticals-13-00095">50</xref>,<xref ref-type="bibr" rid="B51-pharmaceuticals-13-00095">51</xref>,<xref ref-type="bibr" rid="B52-pharmaceuticals-13-00095">52</xref>,<xref ref-type="bibr" rid="B53-pharmaceuticals-13-00095">53</xref>]. CRBN forms a complex with Cullin 4 (Cul4), DDB1, and regulator of Cullins-1 (Roc1) and functions as a substrate of this CRL4 complex (CRL4<sup>CRBN</sup>). The autoubiquitination of CRBN was shown to be inhibited by thalidomide. It was found that the CRBN<sup>Y384A/W386A(YW/AA)</sup> mutant did not bind to thalidomide. The zebrafish and chick developmental model systems were utilized to evaluate whether CRBN was genuinely involved in mediating thalidomide-induced teratogenicity. When CRBN<sup>YW/AA</sup> was overexpressed, the teratogenic phenotypes of thalidomide were reversed in both chicks and zebrafish. The expression of FGF8 was restored by CRBN<sup>YW/AA</sup> expression even after thalidomide treatment. These findings demonstrated that CRBN was a primary target of thalidomide and critically involved in thalidomide teratogenicity.</p>
</sec>
<sec id="sec4-pharmaceuticals-13-00095">
<title>4. CRBN as a Therapeutic Target of Thalidomide and Its Derivatives</title>
<p>The finding that CRBN was a critical, direct target of thalidomide and functioned as a subunit of a CRL4 E3 ligase greatly advanced our understanding of the molecular mechanism of thalidomide and its derivatives. The therapeutic effects of thalidomide and its derivatives, rather than the teratogenic effects, became the focus of further research. As mentioned previously, the remedial effect of thalidomide against multiple myeloma led to the development of its derivatives lenalidomide and pomalidomide—both of which are now approved by the FDA. Pomalidomide is a compound in which an amino group is added to the phthalimide of thalidomide, and lenalidomide has the structure of pomalidomide without the carbonyl group on the phthalimide moiety (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f001">Figure 1</xref>B,C). Both compounds are called immunomodulatory drugs (IMiDs) and are reported to have more potent immunomodulatory activity than thalidomide [<xref ref-type="bibr" rid="B15-pharmaceuticals-13-00095">15</xref>,<xref ref-type="bibr" rid="B54-pharmaceuticals-13-00095">54</xref>].</p>
<p>An intriguing question was whether CRBN was involved in the therapeutic effects of lenalidomide and pomalidomide. In 2011, Stewart and colleagues found that knockdown of CRBN by RNA interference (RNAi) blocked the inhibition of cell proliferation by lenalidomide or pomalidomide in several multiple myeloma cell lines [<xref ref-type="bibr" rid="B55-pharmaceuticals-13-00095">55</xref>]. The group also reported that the expression of CRBN was considerably lower in pomalidomide-resistant cell lines [<xref ref-type="bibr" rid="B55-pharmaceuticals-13-00095">55</xref>]. Celgene Corporation and our group confirmed their data in 2012. We also demonstrated that compounds containing a glutarimide moiety, such as lenalidomide and pomalidomide, bind to CRBN [<xref ref-type="bibr" rid="B56-pharmaceuticals-13-00095">56</xref>], and lenalidomide and pomalidomide bound to CRBN more strongly than thalidomide. These results suggested that CRBN is required not only for the teratogenic effects but also the therapeutic effects of thalidomide and its derivatives.</p>
</sec>
<sec id="sec5-pharmaceuticals-13-00095">
<title>5. Ligand-Dependent Substrate Recognition of CRL4<sup>CRBN</sup></title>
<p>Since CRBN was shown to be involved in the anti-cancer effects of thalidomide and its derivatives, researchers next investigated the relevant CRBN substrates. Since then, several CRBN substrates have been identified.</p>
<sec id="sec5dot1-pharmaceuticals-13-00095">
<title>5.1. Ikaros and Aiolos</title>
<p>In 2014, two independent groups found lenalidomide-dependent CRL4<sup>CRBN</sup> substrates, Ikaros (IKZF1) and Aiolos (IKZF3), in multiple myeloma cell lines [<xref ref-type="bibr" rid="B57-pharmaceuticals-13-00095">57</xref>,<xref ref-type="bibr" rid="B58-pharmaceuticals-13-00095">58</xref>]. Ikaros and Aiolos belong to the Ikaros zinc finger family (IKZF) [<xref ref-type="bibr" rid="B59-pharmaceuticals-13-00095">59</xref>]. In the presence of lenalidomide, Ikaros and Aiolos were polyubiquitinated by CRL4<sup>CRBN</sup> and subsequently degraded in the proteasome. Such ligand-dependent substrates are called neosubstrates. Other IKZF family members, IKZF2 and IKZF4, were not degraded by lenalidomide. The 146th amino acid in Ikaros and 147th in Aiolos is glutamine (Q146 in Ikaros and Q147 in Aiolos), which are replaced with histidine in IKZF2 and IKZF4, respectively. Neither Ikaros<sup>Q146H</sup> nor Aiolos<sup>Q147H</sup> was degraded by lenalidomide, while IKZF4<sup>H188Q</sup> was degraded. In addition, myeloma cell lines expressing Ikaros<sup>Q146H</sup> or Aiolos<sup>Q147H</sup> were resistant to lenalidomide. It was concluded that the anti-myeloma effect of lenalidomide is primarily due to the degradation of Ikaros and Aiolos. Later, Celgene and our group showed that not only lenalidomide but also pomalidomide induced the degradation of Ikaros and Aiolos, resulting in upregulation of interleukin (IL)-2 in T cells [<xref ref-type="bibr" rid="B60-pharmaceuticals-13-00095">60</xref>].</p>
</sec>
<sec id="sec5dot2-pharmaceuticals-13-00095">
<title>5.2. CK1α</title>
<p>Lenalidomide is the only IMiD that is approved for the treatment of myelodysplastic syndrome (MDS) with deletion of chromosome 5q (5q-) [<xref ref-type="bibr" rid="B61-pharmaceuticals-13-00095">61</xref>,<xref ref-type="bibr" rid="B62-pharmaceuticals-13-00095">62</xref>]. However, the mechanism was unclear. In 2015, in addition to Ikaros and Aiolos, casein kinase alpha (CK1α) was identified as a lenalidomide-dependent CRL4<sup>CRBN</sup> neosubstrate [<xref ref-type="bibr" rid="B63-pharmaceuticals-13-00095">63</xref>]. The 5q- MDS cells carry a deletion in the chromosome region containing the CSNK1A1 gene, resulting in haploinsufficient expression of CK1α. In such 5q- cells, the degradation of CK1α by lenalidomide resulted in cell death. Furthermore, this degradation of CK1α by lenalidomide was considerably weaker than that induced by thalidomide or pomalidomide. This finding suggested that the neosubstrates recognized by CRL4<sup>CRBN</sup> differ depending on the ligand.</p>
</sec>
<sec id="sec5dot3-pharmaceuticals-13-00095">
<title>5.3. GSPT1</title>
<p>Celgene has been developing numerous thalidomide derivatives. Among them, CC-885 was shown to possess potent anti-proliferative activity against various cancer cell lines and a noteworthy effect against acute myelogenous leukemia (AML) and AML-derived cell lines. Notably, anti-AML activity was not found in thalidomide or any previously characterized IMiDs. The structure of CC-885 is similar to that of lenalidomide, with an extended structure (a urea and a chloro-methyl-phenyl group) (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f001">Figure 1</xref>D). Our group performed immuno-affinity purification of the CRBN–CC-885 complex and identified a CC-885-dependent neosubstrate, G1-to-S phase transition 1 (GSPT1), also known as eukaryotic peptide chain release factor GTP-binding subunit ERF3A [<xref ref-type="bibr" rid="B64-pharmaceuticals-13-00095">64</xref>]. Biochemical studies have shown that CC-885 induces anti-AML effects via the degradation of GSPT1. Currently, several derivatives of CC-885 have been developed [<xref ref-type="bibr" rid="B65-pharmaceuticals-13-00095">65</xref>]. CC-90009 (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f001">Figure 1</xref>E) is being tested in clinical trials [<xref ref-type="bibr" rid="B66-pharmaceuticals-13-00095">66</xref>].</p>
</sec>
<sec id="sec5dot4-pharmaceuticals-13-00095">
<title>5.4. ZFP91 and Other Zinc Finger Proteins</title>
<p>The search for CRL4<sup>CRBN</sup> neosubstrates has continued and, in 2017, another zinc finger motif-containing neosubstrate was found in the non-hematological cell lines HCT116 (colon cancer) and 293T [<xref ref-type="bibr" rid="B67-pharmaceuticals-13-00095">67</xref>]. This finding suggested the hypothesis that at least a fraction of CRL4<sup>CRBN</sup> neosubstrates share an IKZF-like zinc finger. To further investigate the zinc finger hypothesis, a C2H2 zinc finger library was screened via proteome-wide mass spectrometry. This study identified several new CRL4<sup>CRBN</sup> neosubstrates, including ZNF692 (Zinc Finger Protein 692) [<xref ref-type="bibr" rid="B68-pharmaceuticals-13-00095">68</xref>].</p>
</sec>
</sec>
<sec id="sec6-pharmaceuticals-13-00095">
<title>6. Structure of the CRBN–Drug–Neosubstrate Complex</title>
<p>The structure of the direct target of thalidomide has been intriguing to structural biologists. In 2014, Thoma, Fischer, and colleagues reported the X-ray structure of a chimeric complex of human DDB1 and chick CRBN bound to thalidomide [<xref ref-type="bibr" rid="B69-pharmaceuticals-13-00095">69</xref>]. Celgene and our group also reported the X-ray structure of human CRBN and human DDB1 bound to lenalidomide [<xref ref-type="bibr" rid="B70-pharmaceuticals-13-00095">70</xref>]. Chick CRBN is highly homologous to human CRBN. Chick CRBN is composed of at least three domains, a seven-stranded β-sheet located in the amino-terminal domain (NTD, residues 1–185), an α-helix bundle domain (HBD, residues 186–317) containing seven helices, and a carboxy-terminal domain (CTD, residues 318–445) composed of eight β-sheets. The NTD and the HBD are related to the N-terminus of Lon protease. The structure of DDB1 is composed of three β-propeller blades (BPA, BPB, and BPC). The HBD of CRBN binds BPA and BPC. The CTD contains a zinc finger domain and the thalidomide-binding domain (TBD). The zinc finger consists of C323, C326, C391, and C394 in humans. The physiological significance of the zinc finger is still unknown, but it is noteworthy that the C391R mutation of CRBN was reported to be associated with intellectual disability [<xref ref-type="bibr" rid="B71-pharmaceuticals-13-00095">71</xref>]. TBD possesses three tryptophans (W380, W386, and W400) that form a pocket called the tri-trp pocket. The glutarimide moiety of thalidomide and its derivatives can be inserted into the pocket.</p>
<p>Subsequent reports by these same groups in 2016 showed that the ligands form a molecular glue between CRBN and its neosubstrates. The Thoma group reported the X-ray structure of the CK1α–lenalidomide–CRBN/DDB1 complex and Celgene and our group reported the structure of the GSPT1–CC-885–CRBN/DDB1 complex [<xref ref-type="bibr" rid="B64-pharmaceuticals-13-00095">64</xref>,<xref ref-type="bibr" rid="B72-pharmaceuticals-13-00095">72</xref>]. Both CK1α and GSPT1 contain a β-hairpin motif, which is essential for binding to CRBN. In the CK1α complex, lenalidomide acts as a molecular glue between CRBN and CK1α. The G40 residue of CK1α in the hairpin motif is sandwiched between phthalimide and CRBN. The glycine is critical for the interaction with lenalidomide. One of the carbonyl groups in the phthalimide moiety prevents steric clash. Therefore, lenalidomide degrades CK1α more efficiently than thalidomide or pomalidomide. In the GSPT1 complex, CC-885 connects CRBN to GSPT1. The chloro-methyl-phenyl group of CC-885 is important for binding to GSPT1. The G575 of GSPT1, like the G40 of CK1α, is essential for its interactions with CC-885 and CRBN. The F150 residue of CRBN, which is in the NTD, is important for binding to GSPT1, but is not essential for interactions with CK1α and Ikaros. Although the functions of the NTD of CRBN are still largely unknown, the NTD is required for its interactions with several neosubstrates. In 2018, the structure of CRBN bound to the zinc finger motif of Ikaros or the related neosubstrate ZNF692 in the presence of pomalidomide was determined, and the amino group of pomalidomide was shown to contribute to the interaction with Ikaros/ZNF692 and CRBN [<xref ref-type="bibr" rid="B68-pharmaceuticals-13-00095">68</xref>].</p>
<p>Thalidomide and its derivatives have one chiral center. Thalidomide and other IMiDs are usually used as a mixture of the (S)-isomer and the (R)-isomer. Previously, researchers thought that thalidomide exerts different effects depending on the enantiomer [<xref ref-type="bibr" rid="B73-pharmaceuticals-13-00095">73</xref>]. However, the isomers rapidly racemize under physiological conditions [<xref ref-type="bibr" rid="B74-pharmaceuticals-13-00095">74</xref>]. It therefore remained unclear whether thalidomide acted differently on different optical isomers. Researchers have shown that the (S)-enantiomer bound approximately 10-fold more strongly to CRBN [<xref ref-type="bibr" rid="B70-pharmaceuticals-13-00095">70</xref>,<xref ref-type="bibr" rid="B75-pharmaceuticals-13-00095">75</xref>] than the (R)-enantiomer. The crystal structures of CRBN and each enantiomer revealed that both enantiomers bind the tri-trp pocket. However, the bound form of (S)-enantiomer to CRBN exhibited a more relaxed conformation of its glutarimide ring [<xref ref-type="bibr" rid="B69-pharmaceuticals-13-00095">69</xref>,<xref ref-type="bibr" rid="B70-pharmaceuticals-13-00095">70</xref>,<xref ref-type="bibr" rid="B75-pharmaceuticals-13-00095">75</xref>]. The conformation of the (R)-enantiomer is twisted to avoid steric clashes, resulting in a weaker binding activity. The (S)-enantiomer more effectively decreased Ikaros protein in multiple myeloma and induced fin defects in zebrafish [<xref ref-type="bibr" rid="B75-pharmaceuticals-13-00095">75</xref>]. Although the (R)-enantiomer possesses weak CRBN-binding activity, it might be a supplier of (S)-enantiomer by racemization under physiological conditions.</p>
<p>Through structural biological analyses, species-specific effects of thalidomide and its derivatives have been partly elucidated. In rodents, neither teratogenic effects nor therapeutic effects of thalidomide and its derivatives have been observed [<xref ref-type="bibr" rid="B76-pharmaceuticals-13-00095">76</xref>,<xref ref-type="bibr" rid="B77-pharmaceuticals-13-00095">77</xref>]. Mouse CRBN is 95% homologous to human CRBN and can bind to thalidomide. However, it was shown that lenalidomide and pomalidomide did not degrade neosubstrates such as Ikaros or CK1α in mouse cells or human cells in which CRBN was replaced with mouse CRBN [<xref ref-type="bibr" rid="B63-pharmaceuticals-13-00095">63</xref>]. There are two critical amino acids in human CRBN, E377 and V388. In rodents, these amino acids are substituted to valine and isoleucine, respectively. The V388I substitution of CRBN abolishes the interaction with Ikaros and CK1α in the presence of thalidomide or IMiDs [<xref ref-type="bibr" rid="B63-pharmaceuticals-13-00095">63</xref>]. Structural studies have shown that CRBN binds to Ikaros and CK1α at V388 [<xref ref-type="bibr" rid="B68-pharmaceuticals-13-00095">68</xref>,<xref ref-type="bibr" rid="B72-pharmaceuticals-13-00095">72</xref>]. The V388I mutation induces steric clash and therefore prevents binding. The E377V substitution abolished the interaction with GSPT1 in the presence of CC-885 because E377 binds to the urea of CC-885 [<xref ref-type="bibr" rid="B62-pharmaceuticals-13-00095">62</xref>]. Lenalidomide has been shown to degrade mouse CK1α in “humanized” mouse cells expressing mouse CRBN<sup>I391V</sup> [<xref ref-type="bibr" rid="B63-pharmaceuticals-13-00095">63</xref>]. Researchers constructed humanized mice expressing mouse CRBN<sup>I391V</sup> [<xref ref-type="bibr" rid="B78-pharmaceuticals-13-00095">78</xref>,<xref ref-type="bibr" rid="B79-pharmaceuticals-13-00095">79</xref>] and found that lenalidomide acted on the hematopoietic stem cells in humanized mice. Thalidomide induced fetal loss in these mice, but limb defects were not observed [<xref ref-type="bibr" rid="B79-pharmaceuticals-13-00095">79</xref>]. Thalidomide resistance in rodents therefore remains a mystery.</p>
</sec>
<sec id="sec7-pharmaceuticals-13-00095">
<title>7. Teratogenic Mechanisms Associated With CRBN</title>
<p>While the substrates of thalidomide and its derivatives and their roles in its therapeutic effects have been elucidated, the molecular basis of the teratogenic effects remained unclear. Four downstream factors have been identified as candidate players in thalidomide—CRBN-mediated teratogenicity.</p>
<sec id="sec7dot1-pharmaceuticals-13-00095">
<title>7.1. MEIS2</title>
<p>Fischer and colleagues first performed a structural analysis of DDB1–CRBN bound to thalidomide or its derivatives and evaluated the binding of the known IKZF family neosubstrates. They examined the ubiquitination of approximately 9000 proteins by CRL4<sup>CRBN</sup> using human protein microarrays and identified MEIS2 as a protein that was ubiquitinated by CRBN and was stabilized upon treatment with thalidomide or other IMiDs [<xref ref-type="bibr" rid="B69-pharmaceuticals-13-00095">69</xref>]. MEIS2 had been hypothesized to negatively regulate limb outgrowth [<xref ref-type="bibr" rid="B80-pharmaceuticals-13-00095">80</xref>], which made it an intriguing downstream target of thalidomide. However, whether the accumulation of MEIS2 in response to thalidomide treatment is involved in limb malformation has not been shown to be investigated using any suitable animal model.</p>
</sec>
<sec id="sec7dot2-pharmaceuticals-13-00095">
<title>7.2. CD147</title>
<p>The CD147 (Cluster of Differentiation 147) /MCT1 (Monocarboxylate Transporter 1) complex was identified as a CRBN-binding partner by tandem affinity purification [<xref ref-type="bibr" rid="B81-pharmaceuticals-13-00095">81</xref>]. Lenalidomide acted as a competitive inhibitor of the CRBN–CD147/MCT1 interaction. Inhibition of this interaction destabilized CD147/MCT1, independent of the ubiquitination of CRL4<sup>CRBN</sup> [<xref ref-type="bibr" rid="B81-pharmaceuticals-13-00095">81</xref>]. CD147 is expressed on the surface of multiple myeloma cells and functions as a receptor for secreted cyclophilin A, which promotes aggregation and homing to the bone marrow [<xref ref-type="bibr" rid="B82-pharmaceuticals-13-00095">82</xref>]. Therefore, destabilization of the CD147/MCT1 complex by lenalidomide attenuates cell proliferation. Interestingly, 5q- MDS has elevated expression of CD147 compared with non5q- MDS, which may provide an explanation for the observation that lenalidomide is ineffective in 5q- MDS [<xref ref-type="bibr" rid="B81-pharmaceuticals-13-00095">81</xref>]. In addition to its clinical role, the CD147/MCT1 complex was investigated in the context of thalidomide-induced teratogenicity. Zebrafish in which CD147 had been knocked down showed teratogenic phenotypes such as malformation of the head, pectoral fins, and eyes [<xref ref-type="bibr" rid="B81-pharmaceuticals-13-00095">81</xref>]. Reduced expression of FGF8 was demonstrated in the fin of CD147 knockdown zebrafish [<xref ref-type="bibr" rid="B81-pharmaceuticals-13-00095">81</xref>].</p>
</sec>
<sec id="sec7dot3-pharmaceuticals-13-00095">
<title>7.3. SALL4</title>
<p>In 2018, two independent groups reported a C2H2 zinc finger transcription factor SALL4 (Spalt Like Transcription Factor 4) as a thalidomide-dependent neosubstrate of CRL4<sup>CRBN</sup>. First, Fischer’s group identified neosubstrates that decreased upon thalidomide, lenalidomide, or pomalidomide treatment by mass spectrometry using human embryonic stem cells (hESC), as no animal model was similar enough to mimic thalidomide syndrome in humans [<xref ref-type="bibr" rid="B83-pharmaceuticals-13-00095">83</xref>]. SALL4 was selected from the list of proteins degraded upon thalidomide treatment because it was previously identified as the causal gene of hereditary diseases such as Duane Radial Ray syndrome, Okihiro syndrome and Holt–Oram syndrome [<xref ref-type="bibr" rid="B84-pharmaceuticals-13-00095">84</xref>,<xref ref-type="bibr" rid="B85-pharmaceuticals-13-00095">85</xref>,<xref ref-type="bibr" rid="B86-pharmaceuticals-13-00095">86</xref>]. These syndromes partly overlap with thalidomide embryopathy [<xref ref-type="bibr" rid="B87-pharmaceuticals-13-00095">87</xref>]. In addition, Chamberlain’s group independently identified SALL4 on the basis of its structural similarity with the known zinc finger-type neosubstrates [<xref ref-type="bibr" rid="B88-pharmaceuticals-13-00095">88</xref>]. Both groups showed that degradation of human SALL4 by human CRBN was thalidomide dependent, and the crucial glycine identified for the degradation was G416. In addition, it was shown that mouse SALL4 was not degraded. Chamberlain’s group observed SALL4 degradation in the rabbit fetus, another model animal for thalidomide teratogenicity [<xref ref-type="bibr" rid="B88-pharmaceuticals-13-00095">88</xref>]. Both studies concluded that SALL4 is a neosubstrate responsible for the teratogenic effects of thalidomide.</p>
<p>A follow-up study reported the effects of thalidomide and IMiDs against differentiating human induced pluripotent stem cells (hiPSCs). The authors demonstrated that thalidomide-dependent SALL4 degradation in hiPSCs was abolished by a mutation in CRBN of valine to isoleucine at position V388. Similar effects were observed with SALL4 G416A. These mutations desensitized hiPSCs to the effects of thalidomide or IMiDs upon differentiation to lateral plate mesodermal (LPM)-like cells. The mutated hiPSCs retained sensitivity to inhibition of differentiation by all-trans retinoic acid (atRA) or SB431542, which are other known teratogens. This study suggests that SALL4 may be a crucial neosubstrate involved in limb malformation [<xref ref-type="bibr" rid="B89-pharmaceuticals-13-00095">89</xref>].</p>
<p>The role of SALL4 has been studied in a mouse model. SALL4 knockout mice were embryonic lethal, and in heterozygotes, the phenotype varied; some litters showed phenotypic changes in the heart (interventricular septum loss) and did not survive long, yet those that survived longer than 3 weeks showed no obvious phenotypes of Okihiro syndrome, such as abnormalities in the digits [<xref ref-type="bibr" rid="B90-pharmaceuticals-13-00095">90</xref>]. When SALL4 heterozygotes were crossed with heterozygotes of SALL1, another SALL family member, the pups showed Okihiro syndrome-like phenotypes in the anorectal system, heart, brain, and/or kidneys, and did not survive long. Further, homozygous SALL4 knockout was also lethal in zebrafish, which showed morphological abnormalities in the heart and eyes and had shortened bodies, although the embryos possessed pectoral fins [<xref ref-type="bibr" rid="B91-pharmaceuticals-13-00095">91</xref>].</p>
<p>Indeed, SALL4 had already been proposed to be a downstream target of thalidomide before CRBN was found; Knobloch and Ruther showed in 2008 that SALL4 mRNA decreased upon thalidomide treatment in chickens [<xref ref-type="bibr" rid="B33-pharmaceuticals-13-00095">33</xref>]. This pathway seemingly differs from the thalidomide–CRL4<sup>CRBN</sup> protein degradation axis, and there may be more to be determined about the relationship between thalidomide and SALL4.</p>
</sec>
<sec id="sec7dot4-pharmaceuticals-13-00095">
<title>7.4. p63</title>
<p>Guerrini and colleagues have been studying the TP63 (Tumor Protein P63 or p63) gene [<xref ref-type="bibr" rid="B92-pharmaceuticals-13-00095">92</xref>,<xref ref-type="bibr" rid="B93-pharmaceuticals-13-00095">93</xref>]. TP63 is the causal gene of genetic syndromes with multiple birth defects. Congenital limb malformations, ectodermal dysplasias, and facial clefts are the main characteristics of human patients with TP63 mutations such as ectodermal dysplasia and cleft lip/palate (EEC) syndrome and acro-dermato-ungual-lacrimal-tooth (ADULT) syndrome [<xref ref-type="bibr" rid="B94-pharmaceuticals-13-00095">94</xref>]. In mice, p63 knockout causes abnormalities in the development of epithelial structures, including limbs, and the fins are abolished in zebrafish with p63 knocked down [<xref ref-type="bibr" rid="B95-pharmaceuticals-13-00095">95</xref>,<xref ref-type="bibr" rid="B96-pharmaceuticals-13-00095">96</xref>,<xref ref-type="bibr" rid="B97-pharmaceuticals-13-00095">97</xref>]. Guerrini hypothesized p63 as among the downstream targets of thalidomide. Our group worked together with the Guerrini group on these studies, and our collaborative group identified a relationship between p63 and CRBN. More than ten isomers of p63 have been identified, depending on promoter use and splice variation [<xref ref-type="bibr" rid="B98-pharmaceuticals-13-00095">98</xref>]. We evaluated the major isoforms, ΔNp63α and TAp63α, and found that both isoforms were thalidomide-dependent neosubstrates of CRL4<sup>CRBN</sup> [<xref ref-type="bibr" rid="B40-pharmaceuticals-13-00095">40</xref>]. Although p63 is a non-C2H2 zinc finger-type neosubstrate, we identified a glycine that was important for its degradation, and mutant versions of ΔNp63α and TAp63α were not degraded by thalidomide treatment. Furthermore, zebrafish were used to examine the thalidomide teratogenic effect in animals. ΔNp63 is expressed in the AER and epithelial tissue, while TAp63 is mainly expressed in the heart and the ear [<xref ref-type="bibr" rid="B96-pharmaceuticals-13-00095">96</xref>,<xref ref-type="bibr" rid="B99-pharmaceuticals-13-00095">99</xref>,<xref ref-type="bibr" rid="B100-pharmaceuticals-13-00095">100</xref>]. As mentioned previously, thalidomide-treated zebrafish have abnormalities in the pectoral fins and otic vesicles. When ΔNp63 or TAp63 was knocked down, zebrafish showed defects in the pectoral fins or otic vesicles, respectively. When the non-degraded mutants of ΔNp63 or TAp63 were overexpressed, the abnormal development of the fins or otic vesicles was reversed in thalidomide-treated zebrafish. In addition to these phenotypic observations, the expression of downstream targets was examined in each tissue (FGF8, a crucial regulator of limb/fin development, and Atoh1, an essential transcription factor for the development of sensory neurons and cochlea development) [<xref ref-type="bibr" rid="B100-pharmaceuticals-13-00095">100</xref>]. The expression of both targets was downregulated upon thalidomide exposure or ΔNp63/TAp63 knockdown, respectively. These findings were confirmed with overexpression of non-degraded ΔNp63/TAp63 mutants. Taken together, we concluded that at least in zebrafish, ΔNp63 and TAp63 were thalidomide-dependent CRL4<sup>CRBN</sup> neosubstrates responsible for teratogenicity. Interestingly, there are a few reports demonstrating the protective role of ΔNp63α against oxidative stress. In these papers, ΔNp63α was shown to confer resistance to oxidative stress-induced cell death [<xref ref-type="bibr" rid="B101-pharmaceuticals-13-00095">101</xref>,<xref ref-type="bibr" rid="B102-pharmaceuticals-13-00095">102</xref>]. In addition to FGF8 downregulation, the thalidomide-dependent breakdown of ΔNp63α may increase oxidative stress, which generally fits with the previously mentioned oxidative stress hypothesis. Our study in zebrafish was limited to defects of the limbs and otic vesicles, and thalidomide-dependent malformations in other tissues have not been examined. We cannot exclude the possibility that there are additional CRBN neosubstrates associated with other defects of thalidomide.</p>
<p>With all of these findings taken together, we have now come to understand some part of the mechanism of thalidomide embryopathy; that is, thalidomide binds to its only target, CRBN, which affects various downstream pathways, resulting in the accumulation of MEIS2, the destabilization of CD147/MCT, and the breakdown of multiple neosubstrates such as SALL4, ΔNp63, TAp63, and likely others yet to be identified (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f002">Figure 2</xref>). These changes potentially lead to varied birth defects.</p>
</sec>
</sec>
<sec id="sec8-pharmaceuticals-13-00095">
<title>8. Concluding Remarks</title>
<p>This decade saw remarkable progress in our understanding of the targets and underlying molecular mechanisms of thalidomide. First, thalidomide binds to CRBN, which recruits a neosubstrate, then ubiquitinates the bound neosubstrate. Ubiquitinated neosubstrates are degraded via the ubiquitin–proteasome pathway, and various effects occur, depending on the neosubstrate.</p>
<p>More thalidomide derivatives, now called cereblon E3 ligase modulators (CELMoDs), have been developed and are now being tested in clinical trials [<xref ref-type="bibr" rid="B66-pharmaceuticals-13-00095">66</xref>,<xref ref-type="bibr" rid="B103-pharmaceuticals-13-00095">103</xref>]. CC-122 (avadomide) (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f001">Figure 1</xref>F) has broader effects than IMiDs and is effective against diffuse large B cell lymphomas (DLBCLs) and solid tumors [<xref ref-type="bibr" rid="B104-pharmaceuticals-13-00095">104</xref>,<xref ref-type="bibr" rid="B105-pharmaceuticals-13-00095">105</xref>]. CC-220 (iberdomide) (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f001">Figure 1</xref>G) has stronger Aiolos/Ikalos degradation activity than IMiDs and is being studied for the treatment of systemic lupus erythematosus (SLE) [<xref ref-type="bibr" rid="B106-pharmaceuticals-13-00095">106</xref>,<xref ref-type="bibr" rid="B107-pharmaceuticals-13-00095">107</xref>,<xref ref-type="bibr" rid="B108-pharmaceuticals-13-00095">108</xref>]. Among the most recently developed CELMoDs is CC-92480 (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f001">Figure 1</xref>H), which is being studied for the treatment of lenalidomide-resistant multiple myeloma [<xref ref-type="bibr" rid="B109-pharmaceuticals-13-00095">109</xref>].</p>
<p>Furthermore, new approaches utilizing the drug-dependent CRL4<sup>CRBN</sup> ubiquitination activity are being established. By combining thalidomide or other CRBN-binding compounds with other low-molecular-weight compounds that interact with pathogenic proteins, CRL4<sup>CRBN</sup> can be recruited to degrade specific proteins of interest (POIs). This technology is called Proteolysis-Targeting Chimeras (PROTACs) and was originally proposed by Crews and Deshaies [<xref ref-type="bibr" rid="B110-pharmaceuticals-13-00095">110</xref>]. To achieve this targeted protein degradation approach, many PROTAC molecules are being synthesized and tested for clinical use [<xref ref-type="bibr" rid="B111-pharmaceuticals-13-00095">111</xref>,<xref ref-type="bibr" rid="B112-pharmaceuticals-13-00095">112</xref>,<xref ref-type="bibr" rid="B113-pharmaceuticals-13-00095">113</xref>,<xref ref-type="bibr" rid="B114-pharmaceuticals-13-00095">114</xref>,<xref ref-type="bibr" rid="B115-pharmaceuticals-13-00095">115</xref>]. For example, dBET1 (<xref ref-type="fig" rid="pharmaceuticals-13-00095-f001">Figure 1</xref>I), among the earliest CRBN-based PROTACs to be developed by Bradner and colleagues, is a fusion of thalidomide and JQ1 [<xref ref-type="bibr" rid="B113-pharmaceuticals-13-00095">113</xref>]. JQ1 is an acetylated-lysine-like compound that binds to bromodomain and extra-terminal (BET) motif-containing transcription factors such as BRD4 (Bromodomain containing 4) and exerts its effects by competitively inhibiting the binding of these transcription factors to acetylated histones. As silencing of BRD4 downregulates the expression of the MYC (v-Myc Myelocytomatosis Viral Oncogene Homolog) oncogene, JQ1 is a potent anti-cancer molecule [<xref ref-type="bibr" rid="B116-pharmaceuticals-13-00095">116</xref>]. Nevertheless, dBET1 has improved anti-cancer activity, as it degrades the transcription factor itself directly, which leads to comparatively rapid inhibition.</p>
<p>Although expectations are high for the clinical use of CRBN-binding compounds as a means of targeted protein degradation, the potential for serious adverse effects needs to be taken into consideration. Downstream targets of thalidomide are gradually being identified, but we have a long way to go to completely elucidate the mechanism of teratogenicity. The structural comparison of the therapeutic neosubstrates with the teratogenic neosubstrates might contribute to develop new safer CRBN-binding drugs [<xref ref-type="bibr" rid="B117-pharmaceuticals-13-00095">117</xref>].</p>
<p>Finally, the function of CRBN in the absence of thalidomide or its derivatives remains mostly uncharacterized. As briefly mentioned above, CRBN was originally reported to be related to intellectual disability, and it was also reported that CRBN interacts with the BK<sub>Ca</sub> channel α subunit (Slo) (BK<sub>Ca</sub> stands for Large-conductance Ca<sup>2+</sup>- and voltage-gated big K<sup>+</sup>) [<xref ref-type="bibr" rid="B118-pharmaceuticals-13-00095">118</xref>,<xref ref-type="bibr" rid="B119-pharmaceuticals-13-00095">119</xref>]. The function of CRBN without thalidomide or other drugs has been examined in animals. Forebrain-specific conditional CRBN knockout mice displayed learning disabilities, and knockdown of CRBN in zebrafish impaired brain development [<xref ref-type="bibr" rid="B120-pharmaceuticals-13-00095">120</xref>,<xref ref-type="bibr" rid="B121-pharmaceuticals-13-00095">121</xref>]. These studies suggest that CRBN function is related to the developing brain, but the function of ligand-unbound CRBN remains unknown. Uridine was also reported to bind to CRBN, and a high concentration of uridine mimicked the thalidomide fin deformity in zebrafish [<xref ref-type="bibr" rid="B122-pharmaceuticals-13-00095">122</xref>]. There might be additional natural ligands or metabolites that bind to CRBN [<xref ref-type="bibr" rid="B123-pharmaceuticals-13-00095">123</xref>]. Further understanding of the basic function of CRBN may lead to the discovery of new biological phenomena and will contribute to the development of safer and more effective drugs.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank our colleagues at the Department of Chemical Biology, Tokyo Medical University.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, T.I.; writing—original draft preparation, T.A.-O. and T.I.; writing—review and editing, T.A.-O., T.I. and H.H.; supervision, T.I. and H.H.; funding acquisition, T.I. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI) from the Japanese Society for the Promotion of Science (JSPS) (grant number 18H05502, to T. I.).</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors have no conflicts of interest to declare.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-pharmaceuticals-13-00095">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McBride</surname>
<given-names>W.G.</given-names>
</name>
</person-group>
<article-title>Thalidomide and congenital malformations</article-title>
<source/>Lancet
          <year>1961</year>
<volume>1</volume>
<fpage>358</fpage>
<pub-id pub-id-type="pmid">13783396</pub-id>
</element-citation>
</ref>
<ref id="B2-pharmaceuticals-13-00095">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenz</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Thalidomide and congenital abnormalities</article-title>
<source/>Lancet
          <year>1962</year>
<volume>1</volume>
<fpage>271</fpage>
<lpage>272</lpage>
</element-citation>
</ref>
<ref id="B3-pharmaceuticals-13-00095">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McBride</surname>
<given-names>W.G.</given-names>
</name>
</person-group>
<article-title>Thalidomide embryopathy</article-title>
<source/>Teratology
          <year>1977</year>
<volume>16</volume>
<fpage>79</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1002/tera.1420160113</pub-id>
<pub-id pub-id-type="pmid">331548</pub-id>
</element-citation>
</ref>
<ref id="B4-pharmaceuticals-13-00095">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenz</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>A short history of thalidomide embryopathy</article-title>
<source/>Teratology
          <year>1988</year>
<volume>38</volume>
<fpage>203</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1002/tera.1420380303</pub-id>
<pub-id pub-id-type="pmid">3067415</pub-id>
</element-citation>
</ref>
<ref id="B5-pharmaceuticals-13-00095">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheskin</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Thalidomide in the Treatment of Lepra Reactions</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>1965</year>
<volume>6</volume>
<fpage>303</fpage>
<lpage>306</lpage>
<pub-id pub-id-type="doi">10.1002/cpt196563303</pub-id>
<pub-id pub-id-type="pmid">14296027</pub-id>
</element-citation>
</ref>
<ref id="B6-pharmaceuticals-13-00095">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutierrez-Rodriguez</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Thalidomide. A promising new treatment for rheumatoid arthritis</article-title>
<source/>Arthritis Rheum.
          <year>1984</year>
<volume>27</volume>
<fpage>1118</fpage>
<lpage>1121</lpage>
<pub-id pub-id-type="doi">10.1002/art.1780271006</pub-id>
<pub-id pub-id-type="pmid">6237660</pub-id>
</element-citation>
</ref>
<ref id="B7-pharmaceuticals-13-00095">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamza</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Treatment of Behcet’s disease with thalidomide</article-title>
<source/>Clin. Rheumatol.
          <year>1986</year>
<volume>5</volume>
<fpage>365</fpage>
<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1007/BF02054255</pub-id>
<pub-id pub-id-type="pmid">3780143</pub-id>
</element-citation>
</ref>
<ref id="B8-pharmaceuticals-13-00095">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogelsang</surname>
<given-names>G.B.</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>G.W.</given-names>
</name>
</person-group>
<article-title>Thalidomide for treatment of graft-versus-host disease</article-title>
<source/>Bone Marrow Transplant
          <year>1988</year>
<volume>3</volume>
<fpage>393</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199204163261604</pub-id>
<pub-id pub-id-type="pmid">3056547</pub-id>
</element-citation>
</ref>
<ref id="B9-pharmaceuticals-13-00095">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atra</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>E.I.</given-names>
</name>
</person-group>
<article-title>Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide</article-title>
<source/>Clin. Exp. Rheumatol.
          <year>1993</year>
<volume>11</volume>
<fpage>487</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="pmid">8275583</pub-id>
</element-citation>
</ref>
<ref id="B10-pharmaceuticals-13-00095">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampaio</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Sarno</surname>
<given-names>E.N.</given-names>
</name>
<name>
<surname>Galilly</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cohn</surname>
<given-names>Z.A.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes</article-title>
<source/>J. Exp. Med.
          <year>1991</year>
<volume>173</volume>
<fpage>699</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="doi">10.1084/jem.173.3.699</pub-id>
<pub-id pub-id-type="pmid">1997652</pub-id>
</element-citation>
</ref>
<ref id="B11-pharmaceuticals-13-00095">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreira</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Sampaio</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Zmuidzinas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frindt</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation</article-title>
<source/>J. Exp. Med.
          <year>1993</year>
<volume>177</volume>
<fpage>1675</fpage>
<lpage>1680</lpage>
<pub-id pub-id-type="doi">10.1084/jem.177.6.1675</pub-id>
<pub-id pub-id-type="pmid">8496685</pub-id>
</element-citation>
</ref>
<ref id="B12-pharmaceuticals-13-00095">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makonkawkeyoon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Limson-Pobre</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Schauf</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Thalidomide inhibits the replication of human immunodeficiency virus type 1</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1993</year>
<volume>90</volume>
<fpage>5974</fpage>
<lpage>5978</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.90.13.5974</pub-id>
<pub-id pub-id-type="pmid">8327469</pub-id>
</element-citation>
</ref>
<ref id="B13-pharmaceuticals-13-00095">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Amato</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Loughnan</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Folkman</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Thalidomide is an inhibitor of angiogenesis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1994</year>
<volume>91</volume>
<fpage>4082</fpage>
<lpage>4085</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.91.9.4082</pub-id>
<pub-id pub-id-type="pmid">7513432</pub-id>
</element-citation>
</ref>
<ref id="B14-pharmaceuticals-13-00095">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singhal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Desikan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ayers</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Roberson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Eddlemon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Munshi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Anaissie</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dhodapkar</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antitumor activity of thalidomide in refractory multiple myeloma</article-title>
<source/>N. Engl. J. Med.
          <year>1999</year>
<volume>341</volume>
<fpage>1565</fpage>
<lpage>1571</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM199911183412102</pub-id>
<pub-id pub-id-type="pmid">10564685</pub-id>
</element-citation>
</ref>
<ref id="B15-pharmaceuticals-13-00095">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartlett</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Dredge</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dalgleish</surname>
<given-names>A.G.</given-names>
</name>
</person-group>
<article-title>The evolution of thalidomide and its IMiD derivatives as anticancer agents</article-title>
<source/>Nat. Rev. Cancer
          <year>2004</year>
<volume>4</volume>
<fpage>314</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1038/nrc1323</pub-id>
<pub-id pub-id-type="pmid">15057291</pub-id>
</element-citation>
</ref>
<ref id="B16-pharmaceuticals-13-00095">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melchert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>List</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The thalidomide saga</article-title>
<source/>Int. J. Biochem. Cell Boil.
          <year>2007</year>
<volume>39</volume>
<fpage>1489</fpage>
<lpage>1499</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2007.01.022</pub-id>
</element-citation>
</ref>
<ref id="B17-pharmaceuticals-13-00095">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeldis</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Elsayed</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>STEPS™: A comprehensive program for controlling and monitoring access to thalidomide</article-title>
<source/>Clin. Ther.
          <year>1999</year>
<volume>21</volume>
<fpage>319</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1016/S0149-2918(00)88289-2</pub-id>
<pub-id pub-id-type="pmid">10211535</pub-id>
</element-citation>
</ref>
<ref id="B18-pharmaceuticals-13-00095">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandenburg</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Bwire</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Houn</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sheehan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zeldis</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention</article-title>
<source/>Drug Saf.
          <year>2017</year>
<volume>40</volume>
<fpage>333</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1007/s40264-016-0501-2</pub-id>
<pub-id pub-id-type="pmid">28074423</pub-id>
</element-citation>
</ref>
<ref id="B19-pharmaceuticals-13-00095">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castilla</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Ashton-Prolla</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Barreda-Mejia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Brunoni</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Cavalcanti</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Correa-Neto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Delgadillo</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Dutra</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Felix</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Giraldo</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Thalidomide, a current teratogen in South America</article-title>
<source/>Teratology
          <year>1996</year>
<volume>54</volume>
<fpage>273</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-9926(199612)54:6&lt;273::AID-TERA1&gt;3.0.CO;2-#</pub-id>
<pub-id pub-id-type="pmid">9098920</pub-id>
</element-citation>
</ref>
<ref id="B20-pharmaceuticals-13-00095">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuler-Faccini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Soares</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>de Sousa</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Maximino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Luna</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>I.V.</given-names>
</name>
<name>
<surname>Waldman</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Castilla</surname>
<given-names>E.E.</given-names>
</name>
</person-group>
<article-title>New cases of thalidomide embryopathy in Brazil</article-title>
<source/>Birth Defects Res. Part A Clin. Mol. Teratol.
          <year>2007</year>
<volume>79</volume>
<fpage>671</fpage>
<lpage>672</lpage>
<pub-id pub-id-type="doi">10.1002/bdra.20384</pub-id>
<pub-id pub-id-type="pmid">17676592</pub-id>
</element-citation>
</ref>
<ref id="B21-pharmaceuticals-13-00095">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vianna</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>M.Z.</given-names>
</name>
<name>
<surname>Sanseverino</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Morelo</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>de Lyra Rabello Neto</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lopez-Camelo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Camey</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Schuler-Faccini</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Pharmacoepidemiology and thalidomide embryopathy surveillance in Brazil</article-title>
<source/>Reprod Toxicol.
          <year>2015</year>
<volume>53</volume>
<fpage>63</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/j.reprotox.2015.03.007</pub-id>
<pub-id pub-id-type="pmid">25828060</pub-id>
</element-citation>
</ref>
<ref id="B22-pharmaceuticals-13-00095">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wiley</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>P.G.</given-names>
</name>
</person-group>
<article-title>Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity</article-title>
<source/>Nat. Med.
          <year>1999</year>
<volume>5</volume>
<fpage>582</fpage>
<lpage>585</lpage>
<pub-id pub-id-type="doi">10.1038/8466</pub-id>
<pub-id pub-id-type="pmid">10229238</pub-id>
</element-citation>
</ref>
<ref id="B23-pharmaceuticals-13-00095">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Philbert</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb</article-title>
<source/>J. Pharmacol. Exp. Ther.
          <year>2002</year>
<volume>300</volume>
<fpage>768</fpage>
<lpage>776</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.300.3.768</pub-id>
<pub-id pub-id-type="pmid">11861780</pub-id>
</element-citation>
</ref>
<ref id="B24-pharmaceuticals-13-00095">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knobloch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shaughnessy</surname>
<given-names>J.D.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Ruther</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway</article-title>
<source/>FASEB J.
          <year>2007</year>
<volume>21</volume>
<fpage>1410</fpage>
<lpage>1421</lpage>
<pub-id pub-id-type="doi">10.1096/fj.06-7603com</pub-id>
<pub-id pub-id-type="pmid">17283219</pub-id>
</element-citation>
</ref>
<ref id="B25-pharmaceuticals-13-00095">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Therapontos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Erskine</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Figg</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Vargesson</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2009</year>
<volume>106</volume>
<fpage>8573</fpage>
<lpage>8578</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0901505106</pub-id>
<pub-id pub-id-type="pmid">19433787</pub-id>
</element-citation>
</ref>
<ref id="B26-pharmaceuticals-13-00095">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ogura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hotta</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Imamura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Identification of a primary target of thalidomide teratogenicity</article-title>
<source/>Science
          <year>2010</year>
<volume>327</volume>
<fpage>1345</fpage>
<lpage>1350</lpage>
<pub-id pub-id-type="doi">10.1126/science.1177319</pub-id>
<pub-id pub-id-type="pmid">20223979</pub-id>
</element-citation>
</ref>
<ref id="B27-pharmaceuticals-13-00095">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Myeloid disease: Another action of a thalidomide derivative</article-title>
<source/>Nature
          <year>2015</year>
<volume>523</volume>
<fpage>167</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1038/nature14628</pub-id>
<pub-id pub-id-type="pmid">26131932</pub-id>
</element-citation>
</ref>
<ref id="B28-pharmaceuticals-13-00095">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asatsuma-Okumura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of cereblon-based drugs</article-title>
<source/>Pharmacol. Ther.
          <year>2019</year>
<volume>202</volume>
<fpage>132</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.06.004</pub-id>
<pub-id pub-id-type="pmid">31202702</pub-id>
</element-citation>
</ref>
<ref id="B29-pharmaceuticals-13-00095">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vargesson</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Thalidomide-induced teratogenesis: history and mechanisms</article-title>
<source/>Birth Defects Res. Part C Embryo Today Rev.
          <year>2015</year>
<volume>105</volume>
<fpage>140</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="doi">10.1002/bdrc.21096</pub-id>
</element-citation>
</ref>
<ref id="B30-pharmaceuticals-13-00095">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Teratogenic effects of thalidomide: molecular mechanisms</article-title>
<source/>Cell. Mol. Life Sci.
          <year>2011</year>
<volume>68</volume>
<fpage>1569</fpage>
<lpage>1579</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-010-0619-9</pub-id>
<pub-id pub-id-type="pmid">21207098</pub-id>
</element-citation>
</ref>
<ref id="B31-pharmaceuticals-13-00095">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Stromland</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses</article-title>
<source/>Teratology
          <year>1999</year>
<volume>60</volume>
<fpage>306</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-9926(199911)60:5&lt;306::AID-TERA11&gt;3.0.CO;2-Y</pub-id>
<pub-id pub-id-type="pmid">10525208</pub-id>
</element-citation>
</ref>
<ref id="B32-pharmaceuticals-13-00095">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spouge</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>P.A.</given-names>
</name>
</person-group>
<article-title>Imperforate anus in 700,000 consecutive liveborn infants</article-title>
<source/>Am. J. Med Genet. Suppl.
          <year>1986</year>
<volume>2</volume>
<fpage>151</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320250619</pub-id>
<pub-id pub-id-type="pmid">3146285</pub-id>
</element-citation>
</ref>
<ref id="B33-pharmaceuticals-13-00095">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knobloch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ruther</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects</article-title>
<source/>Cell Cycle
          <year>2008</year>
<volume>7</volume>
<fpage>1121</fpage>
<lpage>1127</lpage>
<pub-id pub-id-type="doi">10.4161/cc.7.9.5793</pub-id>
<pub-id pub-id-type="pmid">18418038</pub-id>
</element-citation>
</ref>
<ref id="B34-pharmaceuticals-13-00095">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname>
<given-names>C.G.</given-names>
</name>
</person-group>
<article-title>Clinical observations on the thalidomide syndrome</article-title>
<source/>Proc. R. Soc. Med.
          <year>1977</year>
<volume>70</volume>
<fpage>225</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1177/003591577707000403</pub-id>
<pub-id pub-id-type="pmid">866320</pub-id>
</element-citation>
</ref>
<ref id="B35-pharmaceuticals-13-00095">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smithells</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>C.G.</given-names>
</name>
</person-group>
<article-title>Recognition of thalidomide defects</article-title>
<source/>J. Med Genet.
          <year>1992</year>
<volume>29</volume>
<fpage>716</fpage>
<lpage>723</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.29.10.716</pub-id>
<pub-id pub-id-type="pmid">1433232</pub-id>
</element-citation>
</ref>
<ref id="B36-pharmaceuticals-13-00095">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vianna</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Schuler-Faccini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Leite</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>de Sousa</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>da Costa</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Dias</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Morelo</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Doriqui</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Maximino</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Sanseverino</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy: new cases and review of the main dysmorphological findings</article-title>
<source/>Clin. Dysmorphol.
          <year>2013</year>
<volume>22</volume>
<fpage>59</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1097/MCD.0b013e32835ffc58</pub-id>
<pub-id pub-id-type="pmid">23448904</pub-id>
</element-citation>
</ref>
<ref id="B37-pharmaceuticals-13-00095">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smithells</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Thalidomide and malformations in Liverpool</article-title>
<source/>Lancet
          <year>1962</year>
<volume>279</volume>
<fpage>1270</fpage>
<lpage>1273</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(62)92367-X</pub-id>
</element-citation>
</ref>
<ref id="B38-pharmaceuticals-13-00095">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Stromland</surname>
<given-names>K.K.</given-names>
</name>
</person-group>
<article-title>What can we learn from the thalidomide experience: An ophthalmologic perspective</article-title>
<source/>Curr. Opin. Ophthalmol.
          <year>2011</year>
<volume>22</volume>
<fpage>356</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1097/ICU.0b013e3283499f24</pub-id>
<pub-id pub-id-type="pmid">21825994</pub-id>
</element-citation>
</ref>
<ref id="B39-pharmaceuticals-13-00095">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Stromland</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ventura</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bandim</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Autism associated with conditions characterized by developmental errors in early embryogenesis: A mini review</article-title>
<source/>Int. J. Dev. Neurosci.
          <year>2005</year>
<volume>23</volume>
<fpage>201</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijdevneu.2004.06.007</pub-id>
<pub-id pub-id-type="pmid">15749246</pub-id>
</element-citation>
</ref>
<ref id="B40-pharmaceuticals-13-00095">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asatsuma-Okumura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>De Simone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Asakawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guerrini</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>P63 is a cereblon substrate involved in thalidomide teratogenicity</article-title>
<source/>Nat. Chem. Biol.
          <year>2019</year>
<volume>15</volume>
<fpage>1077</fpage>
<lpage>1084</lpage>
<pub-id pub-id-type="doi">10.1038/s41589-019-0366-7</pub-id>
<pub-id pub-id-type="pmid">31591562</pub-id>
</element-citation>
</ref>
<ref id="B41-pharmaceuticals-13-00095">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siamwala</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Veeriah</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Priya</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Rajendran</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saran</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nagarajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pradeep</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Nitric oxide rescues thalidomide mediated teratogenicity</article-title>
<source/>Sci. Rep.
          <year>2012</year>
<volume>2</volume>
<fpage>679</fpage>
<pub-id pub-id-type="doi">10.1038/srep00679</pub-id>
<pub-id pub-id-type="pmid">22997553</pub-id>
</element-citation>
</ref>
<ref id="B42-pharmaceuticals-13-00095">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brent</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Drug Testing in Animals for Teratogenic Effects. Thalidomide in the Pregnant Rat</article-title>
<source/>J. Pediatr.
          <year>1964</year>
<volume>64</volume>
<fpage>762</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(64)80626-0</pub-id>
<pub-id pub-id-type="pmid">14149012</pub-id>
</element-citation>
</ref>
<ref id="B43-pharmaceuticals-13-00095">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewandoski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>G.R.</given-names>
</name>
</person-group>
<article-title>Fgf8 signalling from the AER is essential for normal limb development</article-title>
<source/>Nat. Genet.
          <year>2000</year>
<volume>26</volume>
<fpage>460</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="doi">10.1038/82609</pub-id>
<pub-id pub-id-type="pmid">11101846</pub-id>
</element-citation>
</ref>
<ref id="B44-pharmaceuticals-13-00095">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moon</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Capecchi</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Fgf8 is required for outgrowth and patterning of the limbs</article-title>
<source/>Nat. Genet.
          <year>2000</year>
<volume>26</volume>
<fpage>455</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="doi">10.1038/82601</pub-id>
<pub-id pub-id-type="pmid">11101845</pub-id>
</element-citation>
</ref>
<ref id="B45-pharmaceuticals-13-00095">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Philbert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Misregulation of gene expression in the redox-sensitive NF-kappab-dependent limb outgrowth pathway by thalidomide</article-title>
<source/>Dev. Dyn.
          <year>2002</year>
<volume>225</volume>
<fpage>186</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1002/dvdy.10150</pub-id>
<pub-id pub-id-type="pmid">12242718</pub-id>
</element-citation>
</ref>
<ref id="B46-pharmaceuticals-13-00095">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hiramoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aizawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hatakeyama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohba</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hatori</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>High-performance affinity beads for identifying drug receptors</article-title>
<source/>Nat. Biotechnol.
          <year>2000</year>
<volume>18</volume>
<fpage>877</fpage>
<lpage>881</lpage>
<pub-id pub-id-type="doi">10.1038/78496</pub-id>
<pub-id pub-id-type="pmid">10932159</pub-id>
</element-citation>
</ref>
<ref id="B47-pharmaceuticals-13-00095">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishio</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Masaike</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Narimatsu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gokon</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tsubouchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hatakeyama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hanyu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sandhu</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Development of novel magnetic nano-carriers for high-performance affinity purification</article-title>
<source/>Colloids Surf. B Biointerfaces
          <year>2008</year>
<volume>64</volume>
<fpage>162</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1016/j.colsurfb.2008.01.013</pub-id>
<pub-id pub-id-type="pmid">18313904</pub-id>
</element-citation>
</ref>
<ref id="B48-pharmaceuticals-13-00095">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hatakeyama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Tools and methodologies capable of isolating and identifying a target molecule for a bioactive compound</article-title>
<source/>Bioorganic Med Chem
          <year>2012</year>
<volume>20</volume>
<fpage>1990</fpage>
<lpage>2001</lpage>
<pub-id pub-id-type="doi">10.1016/j.bmc.2011.12.022</pub-id>
</element-citation>
</ref>
<ref id="B49-pharmaceuticals-13-00095">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higgins</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Pucilowska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>R.Q.</given-names>
</name>
<name>
<surname>Rooney</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation</article-title>
<source/>Neurology
          <year>2004</year>
<volume>63</volume>
<fpage>1927</fpage>
<lpage>1931</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000146196.01316.A2</pub-id>
<pub-id pub-id-type="pmid">15557513</pub-id>
</element-citation>
</ref>
<ref id="B50-pharmaceuticals-13-00095">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groisman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Polanowska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kuraoka</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Saijo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Drapkin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kisselev</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakatani</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage</article-title>
<source/>Cell
          <year>2003</year>
<volume>113</volume>
<fpage>357</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(03)00316-7</pub-id>
<pub-id pub-id-type="pmid">12732143</pub-id>
</element-citation>
</ref>
<ref id="B51-pharmaceuticals-13-00095">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petroski</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Deshaies</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Function and regulation of cullin-RING ubiquitin ligases</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2005</year>
<volume>6</volume>
<fpage>9</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1038/nrm1547</pub-id>
<pub-id pub-id-type="pmid">15688063</pub-id>
</element-citation>
</ref>
<ref id="B52-pharmaceuticals-13-00095">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angers</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>MacCoss</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery</article-title>
<source/>Nature
          <year>2006</year>
<volume>443</volume>
<fpage>590</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1038/nature05175</pub-id>
<pub-id pub-id-type="pmid">16964240</pub-id>
</element-citation>
</ref>
<ref id="B53-pharmaceuticals-13-00095">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase</article-title>
<source/>Mol. Cell
          <year>2007</year>
<volume>26</volume>
<fpage>775</fpage>
<lpage>780</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2007.06.001</pub-id>
<pub-id pub-id-type="pmid">17588513</pub-id>
</element-citation>
</ref>
<ref id="B54-pharmaceuticals-13-00095">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Behnke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cruickshank</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Grenier</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Klunder</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Plamondon</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids</article-title>
<source/>Bioorganic Med. Chem. Lett.
          <year>1998</year>
<volume>8</volume>
<fpage>333</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="doi">10.1016/S0960-894X(98)00029-8</pub-id>
</element-citation>
</ref>
<ref id="B55-pharmaceuticals-13-00095">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.X.</given-names>
</name>
<name>
<surname>Braggio</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>C.X.</given-names>
</name>
<name>
<surname>Bruins</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Van Wier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>X.B.</given-names>
</name>
<name>
<surname>Bjorklund</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bergsagel</surname>
<given-names>P.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide</article-title>
<source/>Blood
          <year>2011</year>
<volume>118</volume>
<fpage>4771</fpage>
<lpage>4779</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2011-05-356063</pub-id>
<pub-id pub-id-type="pmid">21860026</pub-id>
</element-citation>
</ref>
<ref id="B56-pharmaceuticals-13-00095">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Girona</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mendy</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gandhi</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Karasawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carmel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Abbasian</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide</article-title>
<source/>Leukemia
          <year>2012</year>
<volume>26</volume>
<fpage>2326</fpage>
<lpage>2335</lpage>
<pub-id pub-id-type="doi">10.1038/leu.2012.119</pub-id>
<pub-id pub-id-type="pmid">22552008</pub-id>
</element-citation>
</ref>
<ref id="B57-pharmaceuticals-13-00095">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kronke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title>Lenalidomide induces degradation of IKZF1 and IKZF3</article-title>
<source/>Oncoimmunology
          <year>2014</year>
<volume>3</volume>
<fpage>e941742</fpage>
<pub-id pub-id-type="doi">10.4161/21624011.2014.941742</pub-id>
<pub-id pub-id-type="pmid">25610725</pub-id>
</element-citation>
</ref>
<ref id="B58-pharmaceuticals-13-00095">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Middleton</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Naniong</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Mitsiades</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Bradner</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Kaelin</surname>
<given-names>W.G.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins</article-title>
<source/>Science
          <year>2014</year>
<volume>343</volume>
<fpage>305</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="doi">10.1126/science.1244917</pub-id>
<pub-id pub-id-type="pmid">24292623</pub-id>
</element-citation>
</ref>
<ref id="B59-pharmaceuticals-13-00095">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heizmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kastner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The Ikaros family in lymphocyte development</article-title>
<source/>Curr. Opin. Immunol.
          <year>2018</year>
<volume>51</volume>
<fpage>14</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1016/j.coi.2017.11.005</pub-id>
<pub-id pub-id-type="pmid">29278858</pub-id>
</element-citation>
</ref>
<ref id="B60-pharmaceuticals-13-00095">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandhi</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Havens</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Conklin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Waldman</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Thakurta</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)</article-title>
<source/>Br. J. Haematol.
          <year>2014</year>
<volume>164</volume>
<fpage>811</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1111/bjh.12708</pub-id>
<pub-id pub-id-type="pmid">24328678</pub-id>
</element-citation>
</ref>
<ref id="B61-pharmaceuticals-13-00095">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>List</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kurtin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roe</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Buresh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mahadevan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rimsza</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Heaton</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zeldis</surname>
<given-names>J.B.</given-names>
</name>
</person-group>
<article-title>Efficacy of lenalidomide in myelodysplastic syndromes</article-title>
<source/>N. Engl. J. Med.
          <year>2005</year>
<volume>352</volume>
<fpage>549</fpage>
<lpage>557</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa041668</pub-id>
<pub-id pub-id-type="pmid">15703420</pub-id>
</element-citation>
</ref>
<ref id="B62-pharmaceuticals-13-00095">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>List</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dewald</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Giagounidis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Raza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion</article-title>
<source/>N. Engl. J. Med.
          <year>2006</year>
<volume>355</volume>
<fpage>1456</fpage>
<lpage>1465</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa061292</pub-id>
<pub-id pub-id-type="pmid">17021321</pub-id>
</element-citation>
</ref>
<ref id="B63-pharmaceuticals-13-00095">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kronke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Hollenbach</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>MacBeth</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Udeshi</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Chamberlain</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Gandhi</surname>
<given-names>A.K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS</article-title>
<source/>Nature
          <year>2015</year>
<volume>523</volume>
<fpage>183</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1038/nature14610</pub-id>
<pub-id pub-id-type="pmid">26131937</pub-id>
</element-citation>
</ref>
<ref id="B64-pharmaceuticals-13-00095">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matyskiela</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pagarigan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.Y.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Houston</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase</article-title>
<source/>Nature
          <year>2016</year>
<volume>535</volume>
<fpage>252</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1038/nature18611</pub-id>
<pub-id pub-id-type="pmid">27338790</pub-id>
</element-citation>
</ref>
<ref id="B65-pharmaceuticals-13-00095">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Condroski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Correa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Ruchelman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Vocanson</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Crea</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Protein Degradation via CRL4(CRBN) Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1</article-title>
<source/>J. Med. Chem.
          <year>2018</year>
<volume>61</volume>
<fpage>492</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01911</pub-id>
<pub-id pub-id-type="pmid">28358507</pub-id>
</element-citation>
</ref>
<ref id="B66-pharmaceuticals-13-00095">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chamberlain</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Hamann</surname>
<given-names>L.G.</given-names>
</name>
</person-group>
<article-title>Development of targeted protein degradation therapeutics</article-title>
<source/>Nat. Chem. Biol.
          <year>2019</year>
<volume>15</volume>
<fpage>937</fpage>
<lpage>944</lpage>
<pub-id pub-id-type="doi">10.1038/s41589-019-0362-y</pub-id>
<pub-id pub-id-type="pmid">31527835</pub-id>
</element-citation>
</ref>
<ref id="B67-pharmaceuticals-13-00095">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ponthier</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Sack</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Seebacher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stadler</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>E.S.</given-names>
</name>
</person-group>
<article-title>pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase</article-title>
<source/>Nat. Commun.
          <year>2017</year>
<volume>8</volume>
<fpage>15398</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms15398</pub-id>
<pub-id pub-id-type="pmid">28530236</pub-id>
</element-citation>
</ref>
<ref id="B68-pharmaceuticals-13-00095">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sievers</surname>
<given-names>Q.L.</given-names>
</name>
<name>
<surname>Petzold</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bunker</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Renneville</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Slabicki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liddicoat</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Abdulrahman</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mikkelsen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Thoma</surname>
<given-names>N.H.</given-names>
</name>
</person-group>
<article-title>Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN</article-title>
<source/>Science
          <year>2018</year>
<volume>362</volume>
<pub-id pub-id-type="doi">10.1126/science.aat0572</pub-id>
</element-citation>
</ref>
<ref id="B69-pharmaceuticals-13-00095">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Bohm</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lydeard</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Stadler</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Cavadini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nagel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Serluca</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Acker</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lingaraju</surname>
<given-names>G.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide</article-title>
<source/>Nature
          <year>2014</year>
<volume>512</volume>
<fpage>49</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1038/nature13527</pub-id>
<pub-id pub-id-type="pmid">25043012</pub-id>
</element-citation>
</ref>
<ref id="B70-pharmaceuticals-13-00095">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chamberlain</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Lopez-Girona</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Carmel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pagarigan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chie-Leon</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rychak</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Corral</surname>
<given-names>L.G.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs</article-title>
<source/>Nat. Struct. Mol. Biol.
          <year>2014</year>
<volume>21</volume>
<fpage>803</fpage>
<lpage>809</lpage>
<pub-id pub-id-type="doi">10.1038/nsmb.2874</pub-id>
<pub-id pub-id-type="pmid">25108355</pub-id>
</element-citation>
</ref>
<ref id="B71-pharmaceuticals-13-00095">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheereen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alaamery</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bawazeer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Al Yafee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Massadeh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eyaid</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>A missense mutation in the CRBN gene that segregates with intellectual disability and self-mutilating behaviour in a consanguineous Saudi family</article-title>
<source/>J. Med. Genet.
          <year>2017</year>
<volume>54</volume>
<fpage>236</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2016-104117</pub-id>
<pub-id pub-id-type="pmid">28143899</pub-id>
</element-citation>
</ref>
<ref id="B72-pharmaceuticals-13-00095">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petzold</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Thoma</surname>
<given-names>N.H.</given-names>
</name>
</person-group>
<article-title>Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase</article-title>
<source/>Nature
          <year>2016</year>
<volume>532</volume>
<fpage>127</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1038/nature16979</pub-id>
<pub-id pub-id-type="pmid">26909574</pub-id>
</element-citation>
</ref>
<ref id="B73-pharmaceuticals-13-00095">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blaschke</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kraft</surname>
<given-names>H.P.</given-names>
</name>
<name>
<surname>Fickentscher</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kohler</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>[Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers (author’s transl)]</article-title>
<source/>Arzneimittelforschung
          <year>1979</year>
<volume>29</volume>
<fpage>1640</fpage>
<lpage>1642</lpage>
<pub-id pub-id-type="pmid">583234</pub-id>
</element-citation>
</ref>
<ref id="B74-pharmaceuticals-13-00095">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects</article-title>
<source/>Chem. Pharm. Bull. (Tokyo)
          <year>1994</year>
<volume>42</volume>
<fpage>1157</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="doi">10.1248/cpb.42.1157</pub-id>
<pub-id pub-id-type="pmid">8069968</pub-id>
</element-citation>
</ref>
<ref id="B75-pharmaceuticals-13-00095">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tokunaga</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Handa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hakoshima</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Structural basis of thalidomide enantiomer binding to cereblon</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>1294</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-19202-7</pub-id>
<pub-id pub-id-type="pmid">29358579</pub-id>
</element-citation>
</ref>
<ref id="B76-pharmaceuticals-13-00095">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fratta</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Sigg</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Maiorana</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Teratogenic Effects of Thalidomide in Rabbits, Rats, Hamsters, and Mice</article-title>
<source/>Toxicol. Appl. Pharmacol.
          <year>1965</year>
<volume>7</volume>
<fpage>268</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1016/0041-008X(65)90095-5</pub-id>
<pub-id pub-id-type="pmid">14298018</pub-id>
</element-citation>
</ref>
<ref id="B77-pharmaceuticals-13-00095">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chesi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Matthews</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Garbitt</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Shortt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lefebure</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Johnstone</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Bergsagel</surname>
<given-names>P.L.</given-names>
</name>
</person-group>
<article-title>Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy</article-title>
<source/>Blood
          <year>2012</year>
<volume>120</volume>
<fpage>376</fpage>
<lpage>385</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2012-02-412783</pub-id>
<pub-id pub-id-type="pmid">22451422</pub-id>
</element-citation>
</ref>
<ref id="B78-pharmaceuticals-13-00095">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gemechu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Millrine</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sanchenkova</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Metwally</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gyanu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2018</year>
<volume>115</volume>
<fpage>11802</fpage>
<lpage>11807</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1814446115</pub-id>
<pub-id pub-id-type="pmid">30373817</pub-id>
</element-citation>
</ref>
<ref id="B79-pharmaceuticals-13-00095">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>McConkey</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>D.N.</given-names>
</name>
<name>
<surname>Haldar</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Guirguis</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Udeshi</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liddicoat</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Crbn (I391V) is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice</article-title>
<source/>Blood
          <year>2018</year>
<volume>132</volume>
<fpage>1535</fpage>
<lpage>1544</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2018-05-852798</pub-id>
<pub-id pub-id-type="pmid">30064974</pub-id>
</element-citation>
</ref>
<ref id="B80-pharmaceuticals-13-00095">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capdevila</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tsukui</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rodriquez Esteban</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zappavigna</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Izpisua Belmonte</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Control of vertebrate limb outgrowth by the proximal factor Meis2 and distal antagonism of BMPs by Gremlin</article-title>
<source/>Mol. Cell
          <year>1999</year>
<volume>4</volume>
<fpage>839</fpage>
<lpage>849</lpage>
<pub-id pub-id-type="doi">10.1016/S1097-2765(00)80393-7</pub-id>
<pub-id pub-id-type="pmid">10619030</pub-id>
</element-citation>
</ref>
<ref id="B81-pharmaceuticals-13-00095">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichner</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Heider</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fernandez-Saiz</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>van Bebber</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Garz</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Lemeer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rudelius</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Targosz</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Knorn</surname>
<given-names>A.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity</article-title>
<source/>Nat. Med.
          <year>2016</year>
<volume>22</volume>
<fpage>735</fpage>
<lpage>743</lpage>
<pub-id pub-id-type="doi">10.1038/nm.4128</pub-id>
<pub-id pub-id-type="pmid">27294876</pub-id>
</element-citation>
</ref>
<ref id="B82-pharmaceuticals-13-00095">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Calimeri</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hideshima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fulciniti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ficarro</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>Y.T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells</article-title>
<source/>Nat. Med.
          <year>2015</year>
<volume>21</volume>
<fpage>572</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="doi">10.1038/nm.3867</pub-id>
<pub-id pub-id-type="pmid">26005854</pub-id>
</element-citation>
</ref>
<ref id="B83-pharmaceuticals-13-00095">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donovan</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>E.S.</given-names>
</name>
</person-group>
<article-title>Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome</article-title>
<source/>Elife
          <year>2018</year>
<volume>7</volume>
<pub-id pub-id-type="doi">10.7554/eLife.38430</pub-id>
<pub-id pub-id-type="pmid">30067223</pub-id>
</element-citation>
</ref>
<ref id="B84-pharmaceuticals-13-00095">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Baradie</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>St Hilaire</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McIntosh</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nakano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martonyi</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>W.R.</given-names>
</name>
<name>
<surname>Okumura</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Duane radial ray syndrome (Okihiro syndrome) maps to 20q13 and results from mutations in SALL4, a new member of the SAL family</article-title>
<source/>Am. J. Hum. Genet.
          <year>2002</year>
<volume>71</volume>
<fpage>1195</fpage>
<lpage>1199</lpage>
<pub-id pub-id-type="doi">10.1086/343821</pub-id>
<pub-id pub-id-type="pmid">12395297</pub-id>
</element-citation>
</ref>
<ref id="B85-pharmaceuticals-13-00095">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohlhase</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Heinrich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liebers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kispert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Laccone</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Turnpenny</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Winter</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Reardon</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Okihiro syndrome is caused by SALL4 mutations</article-title>
<source/>Hum. Mol. Genet.
          <year>2002</year>
<volume>11</volume>
<fpage>2979</fpage>
<lpage>2987</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/11.23.2979</pub-id>
<pub-id pub-id-type="pmid">12393809</pub-id>
</element-citation>
</ref>
<ref id="B86-pharmaceuticals-13-00095">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohlhase</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liebers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rauch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mohammed</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Newbury-Ecob</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reardon</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy</article-title>
<source/>J. Med. Genet.
          <year>2003</year>
<volume>40</volume>
<fpage>473</fpage>
<lpage>478</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.40.7.473</pub-id>
<pub-id pub-id-type="pmid">12843316</pub-id>
</element-citation>
</ref>
<ref id="B87-pharmaceuticals-13-00095">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohlhase</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>L.B.</given-names>
</name>
</person-group>
<article-title>Mutations in SALL4 in malformed father and daughter postulated previously due to reflect mutagenesis by thalidomide</article-title>
<source/>Birth Defects Res. Part A Clin. Mol. Teratol.
          <year>2004</year>
<volume>70</volume>
<fpage>550</fpage>
<lpage>551</lpage>
<pub-id pub-id-type="doi">10.1002/bdra.20050</pub-id>
<pub-id pub-id-type="pmid">15329836</pub-id>
</element-citation>
</ref>
<ref id="B88-pharmaceuticals-13-00095">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matyskiela</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Couto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stamp</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Drew</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate</article-title>
<source/>Nat. Chem. Biol.
          <year>2018</year>
<volume>14</volume>
<fpage>981</fpage>
<lpage>987</lpage>
<pub-id pub-id-type="doi">10.1038/s41589-018-0129-x</pub-id>
<pub-id pub-id-type="pmid">30190590</pub-id>
</element-citation>
</ref>
<ref id="B89-pharmaceuticals-13-00095">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belair</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Waller</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Gustin</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Kolaja</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4</article-title>
<source/>Sci. Rep.
          <year>2020</year>
<volume>10</volume>
<fpage>2864</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-020-59542-x</pub-id>
<pub-id pub-id-type="pmid">32071327</pub-id>
</element-citation>
</ref>
<ref id="B90-pharmaceuticals-13-00095">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakaki-Yumoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fujimura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takasato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kodama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Aburatani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Asashima</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The murine homolog of SALL4, a causative gene in Okihiro syndrome, is essential for embryonic stem cell proliferation, and cooperates with Sall1 in anorectal, heart, brain and kidney development</article-title>
<source/>Development
          <year>2006</year>
<volume>133</volume>
<fpage>3005</fpage>
<lpage>3013</lpage>
<pub-id pub-id-type="doi">10.1242/dev.02457</pub-id>
<pub-id pub-id-type="pmid">16790473</pub-id>
</element-citation>
</ref>
<ref id="B91-pharmaceuticals-13-00095">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asakawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Protocadherin-Mediated Cell Repulsion Controls the Central Topography and Efferent Projections of the Abducens Nucleus</article-title>
<source/>Cell Rep.
          <year>2018</year>
<volume>24</volume>
<fpage>1562</fpage>
<lpage>1572</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.024</pub-id>
<pub-id pub-id-type="pmid">30089266</pub-id>
</element-citation>
</ref>
<ref id="B92-pharmaceuticals-13-00095">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerrini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Costanzo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Merlo</surname>
<given-names>G.R.</given-names>
</name>
</person-group>
<article-title>A symphony of regulations centered on p63 to control development of ectoderm-derived structures</article-title>
<source/>J. Biomed. Biotechnol.
          <year>2011</year>
<volume>2011</volume>
<fpage>864904</fpage>
<pub-id pub-id-type="doi">10.1155/2011/864904</pub-id>
<pub-id pub-id-type="pmid">21716671</pub-id>
</element-citation>
</ref>
<ref id="B93-pharmaceuticals-13-00095">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Restelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lopardo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lo Iacono</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Garaffo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Conte</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rustighi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Napoli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Del Sal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Perez-Morga</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Costanzo</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DLX5, FGF8 and the Pin1 isomerase control DeltaNp63alpha protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations</article-title>
<source/>Hum. Mol. Genet.
          <year>2014</year>
<volume>23</volume>
<fpage>3830</fpage>
<lpage>3842</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu096</pub-id>
<pub-id pub-id-type="pmid">24569166</pub-id>
</element-citation>
</ref>
<ref id="B94-pharmaceuticals-13-00095">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rinne</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>van Bokhoven</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>H.G.</given-names>
</name>
</person-group>
<article-title>Pattern of p63 mutations and their phenotypes--update</article-title>
<source/>Am. J. Med. Genet. A
          <year>2006</year>
<volume>140</volume>
<fpage>1396</fpage>
<lpage>1406</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.31271</pub-id>
<pub-id pub-id-type="pmid">16691622</pub-id>
</element-citation>
</ref>
<ref id="B95-pharmaceuticals-13-00095">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mills</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Roop</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>P63 is a p53 homologue required for limb and epidermal morphogenesis</article-title>
<source/>Nature
          <year>1999</year>
<volume>398</volume>
<fpage>708</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="doi">10.1038/19531</pub-id>
<pub-id pub-id-type="pmid">10227293</pub-id>
</element-citation>
</ref>
<ref id="B96-pharmaceuticals-13-00095">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schweitzer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kaghad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bronson</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Tabin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sharpe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Caput</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Crum</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>P63 is essential for regenerative proliferation in limb, craniofacial and epithelial development</article-title>
<source/>Nature
          <year>1999</year>
<volume>398</volume>
<fpage>714</fpage>
<lpage>718</lpage>
<pub-id pub-id-type="doi">10.1038/19539</pub-id>
<pub-id pub-id-type="pmid">10227294</pub-id>
</element-citation>
</ref>
<ref id="B97-pharmaceuticals-13-00095">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Beasley</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>A Zebrafish Model for Studies on Esophageal Epithelial Biology</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0143878</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0143878</pub-id>
<pub-id pub-id-type="pmid">26630178</pub-id>
</element-citation>
</ref>
<ref id="B98-pharmaceuticals-13-00095">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaghad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Caput</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>McKeon</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>On the shoulders of giants: p63, p73 and the rise of p53</article-title>
<source/>Trends Genet.
          <year>2002</year>
<volume>18</volume>
<fpage>90</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1016/S0168-9525(02)02595-7</pub-id>
<pub-id pub-id-type="pmid">11818141</pub-id>
</element-citation>
</ref>
<ref id="B99-pharmaceuticals-13-00095">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rouleau</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Medawar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hamon</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shivtiel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wolchinsky</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>De Rosa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Candi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>de la Forest Divonne</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mikkola</surname>
<given-names>M.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TAp63 is important for cardiac differentiation of embryonic stem cells and heart development</article-title>
<source/>Stem Cells
          <year>2011</year>
<volume>29</volume>
<fpage>1672</fpage>
<lpage>1683</lpage>
<pub-id pub-id-type="doi">10.1002/stem.723</pub-id>
<pub-id pub-id-type="pmid">21898690</pub-id>
</element-citation>
</ref>
<ref id="B100-pharmaceuticals-13-00095">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terrinoni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Serra</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bruno</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Strasser</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Valente</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>van Bokhoven</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Melino</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Role of p63 and the Notch pathway in cochlea development and sensorineural deafness</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>7300</fpage>
<lpage>7305</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1214498110</pub-id>
<pub-id pub-id-type="pmid">23589895</pub-id>
</element-citation>
</ref>
<ref id="B101-pharmaceuticals-13-00095">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Viticchie</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lena</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Piro</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Annicchiarico-Petruzzelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Melino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Candi</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>DeltaNp63 targets cytoglobin to inhibit oxidative stress-induced apoptosis in keratinocytes and lung cancer</article-title>
<source/>Oncogene
          <year>2016</year>
<volume>35</volume>
<fpage>1493</fpage>
<lpage>1503</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2015.222</pub-id>
<pub-id pub-id-type="pmid">26096935</pub-id>
</element-citation>
</ref>
<ref id="B102-pharmaceuticals-13-00095">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>G.X.</given-names>
</name>
<name>
<surname>Tu</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Skanderup</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ganesan</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>J.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DeltaNp63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival</article-title>
<source/>Cell Rep.
          <year>2017</year>
<volume>21</volume>
<fpage>2926</fpage>
<lpage>2939</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2017.11.030</pub-id>
<pub-id pub-id-type="pmid">29212036</pub-id>
</element-citation>
</ref>
<ref id="B103-pharmaceuticals-13-00095">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chamberlain</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Cathers</surname>
<given-names>B.E.</given-names>
</name>
</person-group>
<article-title>Cereblon modulators: Low molecular weight inducers of protein degradation</article-title>
<source/>Drug Discov. Today Technol.
          <year>2019</year>
<volume>31</volume>
<fpage>29</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.ddtec.2019.02.004</pub-id>
<pub-id pub-id-type="pmid">31200856</pub-id>
</element-citation>
</ref>
<ref id="B104-pharmaceuticals-13-00095">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagner</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Fontanillo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Couto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Breider</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bjorklund</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Havens</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rychak</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL</article-title>
<source/>Blood
          <year>2015</year>
<volume>126</volume>
<fpage>779</fpage>
<lpage>789</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2015-02-628669</pub-id>
<pub-id pub-id-type="pmid">26002965</pub-id>
</element-citation>
</ref>
<ref id="B105-pharmaceuticals-13-00095">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rasco</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Pourdehnad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gandhi</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Hagner</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chopra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hege</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>DiMartino</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies</article-title>
<source/>Clin. Cancer Res.
          <year>2019</year>
<volume>25</volume>
<fpage>90</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1203</pub-id>
<pub-id pub-id-type="pmid">30201761</pub-id>
</element-citation>
</ref>
<ref id="B106-pharmaceuticals-13-00095">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matyskiela</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Khambatta</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Baculi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hickman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>LeBrun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pagarigan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Carmel</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos</article-title>
<source/>J. Med. Chem.
          <year>2018</year>
<volume>61</volume>
<fpage>535</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01921</pub-id>
<pub-id pub-id-type="pmid">28425720</pub-id>
</element-citation>
</ref>
<ref id="B107-pharmaceuticals-13-00095">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schafer</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kosek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ringheim</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Palmisano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chopra</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus</article-title>
<source/>Ann. Rheum. Dis.
          <year>2018</year>
<volume>77</volume>
<fpage>1516</fpage>
<lpage>1523</lpage>
<pub-id pub-id-type="doi">10.1136/annrheumdis-2017-212916</pub-id>
<pub-id pub-id-type="pmid">29945920</pub-id>
</element-citation>
</ref>
<ref id="B108-pharmaceuticals-13-00095">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjorklund</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Amatangelo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Polonskaia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Couto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN</article-title>
<source/>Leukemia
          <year>2019</year>
<volume>34</volume>
<fpage>1197</fpage>
<lpage>1201</lpage>
<pub-id pub-id-type="doi">10.1038/s41375-019-0620-8</pub-id>
<pub-id pub-id-type="pmid">31719682</pub-id>
</element-citation>
</ref>
<ref id="B109-pharmaceuticals-13-00095">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Correa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Plantevin</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Whitefield</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kercher</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma</article-title>
<source/>J. Med. Chem.
          <year>2020</year>
<pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01928</pub-id>
</element-citation>
</ref>
<ref id="B110-pharmaceuticals-13-00095">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakamoto</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Kumagai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mercurio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Crews</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Deshaies</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2001</year>
<volume>98</volume>
<fpage>8554</fpage>
<lpage>8559</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.141230798</pub-id>
<pub-id pub-id-type="pmid">11438690</pub-id>
</element-citation>
</ref>
<ref id="B111-pharmaceuticals-13-00095">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Toure</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hellerschmied</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Salami</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jaime-Figueroa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hines</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Crews</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</article-title>
<source/>Angew. Chem. Int. Ed. Engl.
          <year>2016</year>
<volume>55</volume>
<fpage>807</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="doi">10.1002/anie.201507634</pub-id>
<pub-id pub-id-type="pmid">26593377</pub-id>
</element-citation>
</ref>
<ref id="B112-pharmaceuticals-13-00095">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burslem</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Crews</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery</article-title>
<source/>Cell
          <year>2020</year>
<volume>181</volume>
<fpage>102</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2019.11.031</pub-id>
<pub-id pub-id-type="pmid">31955850</pub-id>
</element-citation>
</ref>
<ref id="B113-pharmaceuticals-13-00095">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winter</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Paulk</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dhe-Paganon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bradner</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation</article-title>
<source/>Science
          <year>2015</year>
<volume>348</volume>
<fpage>1376</fpage>
<lpage>1381</lpage>
<pub-id pub-id-type="doi">10.1126/science.aab1433</pub-id>
<pub-id pub-id-type="pmid">25999370</pub-id>
</element-citation>
</ref>
<ref id="B114-pharmaceuticals-13-00095">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silva</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Nandi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Patnaik</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Lucente</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>B.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models</article-title>
<source/>Elife
          <year>2019</year>
<volume>8</volume>
<fpage>8</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.45457</pub-id>
<pub-id pub-id-type="pmid">30907729</pub-id>
</element-citation>
</ref>
<ref id="B115-pharmaceuticals-13-00095">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Safaee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Donovan</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Nabet</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gero</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Feru</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exploring Targeted Degradation Strategy for Oncogenic KRAS(G12C)</article-title>
<source/>Cell Chem. Biol.
          <year>2020</year>
<volume>27</volume>
<fpage>19</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.chembiol.2019.12.006</pub-id>
<pub-id pub-id-type="pmid">31883964</pub-id>
</element-citation>
</ref>
<ref id="B116-pharmaceuticals-13-00095">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filippakopoulos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Picaud</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>W.B.</given-names>
</name>
<name>
<surname>Fedorov</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Morse</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Keates</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hickman</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Felletar</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Selective inhibition of BET bromodomains</article-title>
<source/>Nature
          <year>2010</year>
<volume>468</volume>
<fpage>1067</fpage>
<lpage>1073</lpage>
<pub-id pub-id-type="doi">10.1038/nature09504</pub-id>
<pub-id pub-id-type="pmid">20871596</pub-id>
</element-citation>
</ref>
<ref id="B117-pharmaceuticals-13-00095">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matyskiela</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Clayton</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Mayne</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tran</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carpenter</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pagarigan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rolfe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hamann</surname>
<given-names>L.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex</article-title>
<source/>Nat. Struct. Mol. Biol.
          <year>2020</year>
<volume>27</volume>
<fpage>319</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1038/s41594-020-0405-9</pub-id>
<pub-id pub-id-type="pmid">32251415</pub-id>
</element-citation>
</ref>
<ref id="B118-pharmaceuticals-13-00095">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>Y.K.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>C.S.</given-names>
</name>
</person-group>
<article-title>Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain</article-title>
<source/>J. Neurochem.
          <year>2005</year>
<volume>94</volume>
<fpage>1212</fpage>
<lpage>1224</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03344.x</pub-id>
<pub-id pub-id-type="pmid">16045448</pub-id>
</element-citation>
</ref>
<ref id="B119-pharmaceuticals-13-00095">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>CRL4A(CRBN) E3 ubiquitin ligase restricts BK channel activity and prevents epileptogenesis</article-title>
<source/>Nat. Commun.
          <year>2014</year>
<volume>5</volume>
<fpage>3924</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms4924</pub-id>
<pub-id pub-id-type="pmid">24845235</pub-id>
</element-citation>
</ref>
<ref id="B120-pharmaceuticals-13-00095">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajadhyaksha</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Ra</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kishinevsky</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Romanienko</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>DuBoff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zupan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Daruwalla</surname>
<given-names>Z.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Behavioral characterization of cereblon forebrain-specific conditional null mice: a model for human non-syndromic intellectual disability</article-title>
<source/>Behav. Brain Res.
          <year>2012</year>
<volume>226</volume>
<fpage>428</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2011.09.039</pub-id>
<pub-id pub-id-type="pmid">21995942</pub-id>
</element-citation>
</ref>
<ref id="B121-pharmaceuticals-13-00095">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ando</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nitta</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Asatsuma-Okumura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mizushima</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cereblon Control of Zebrafish Brain Size by Regulation of Neural Stem Cell Proliferation</article-title>
<source/>iScience
          <year>2019</year>
<volume>15</volume>
<fpage>95</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1016/j.isci.2019.04.007</pub-id>
<pub-id pub-id-type="pmid">31055217</pub-id>
</element-citation>
</ref>
<ref id="B122-pharmaceuticals-13-00095">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartmann</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Boichenko</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Coles</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zanini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lupas</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Hernandez Alvarez</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Thalidomide mimics uridine binding to an aromatic cage in cereblon</article-title>
<source/>J. Struct. Biol.
          <year>2014</year>
<volume>188</volume>
<fpage>225</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsb.2014.10.010</pub-id>
<pub-id pub-id-type="pmid">25448889</pub-id>
</element-citation>
</ref>
<ref id="B123-pharmaceuticals-13-00095">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boichenko</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Deiss</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Heim</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lupas</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Hernandez Alvarez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>Chemical Ligand Space of Cereblon</article-title>
<source/>ACS Omega
          <year>2018</year>
<volume>3</volume>
<fpage>11163</fpage>
<lpage>11171</lpage>
<pub-id pub-id-type="doi">10.1021/acsomega.8b00959</pub-id>
<pub-id pub-id-type="pmid">31459225</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="pharmaceuticals-13-00095-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Structure of CRBN-binding drugs. (<bold>A</bold>) Thalidomide. (<bold>B</bold>) Lenalidomide. (<bold>C</bold>) Pomalidomide. (<bold>D</bold>) CC-885. (<bold>E</bold>) CC-90009 (<bold>F</bold>) CC-122. (<bold>G</bold>) CC-220. (<bold>H</bold>) CC-92480. (<bold>I</bold>) dBET1, composed of JQ1 (a BRD4 inhibitor) and thalidomide.</p>
</caption>
<graphic xlink:href="pharmaceuticals-13-00095-g001"></graphic>
</fig>
<fig id="pharmaceuticals-13-00095-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Model of the molecular mechanism of thalidomide. Thalidomide exerts multiple functions after binding to CRBN: (i) the non-ubiquitination process of destabilizing the CD147/MCT1 complex, (ii) the blockade of ubiquitination that stabilizes MEIS2, and (iii) the ubiquitin-dependent degradation of several neosubstrates including SALL4 and p63. These multiple downstream targets of the thalidomide–CRBN axis result in the various effects of thalidomide.</p>
</caption>
<graphic xlink:href="pharmaceuticals-13-00095-g002"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>